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Molecular Mechanism of Vitamin D Action and  
its Implications in Ovarian Cancer Prevention and Therapy 
Feng Jiang 
ABSTRACT 
           1,25-dihydroxyvitamin D3 (1,25VD), the active form of vitamin D (VD), 
suppresses the growth of numerous human cancer cell lines by inhibiting cell cycle 
progression and inducing cell death. Genes that mediate each of these activities remain 
largely unidentified and there are no preclinical data for 1,25VD analogues in ovarian 
cancer (OCa). We hypothesize that 1,25VD and its analogues inhibit the development of 
OCa. In this study, we demonstrated, (a) 1,25VD causes cell cycle arrest at the G1/S and 
G2/M transition and induces apoptosis in OCa cells. (b) We also found that gadd45 is one 
of primary target genes for 1,25VD-mediated G2/M arrest. A direct repeat 3 (DR3) 
vitamin D response element (VDRE) is identified in the fourth exon of gadd45. This 
exonic VDRE forms a complex with the vitamin D receptor (VDR)/retinoid X receptor 
(RXR) heterodimer in vitro and mediates the induction of reporter activity by 1,25VD in 
vivo. VDR is recruited in a ligand-dependent manner to the exonic enhancer but not to the 
gadd45 promoter regions. In OCa cells expressing GADD45 anti-sense cDNA or 
GADD45-null mouse embryo fibroblasts, 1,25VD fails to induce G2/M arrest, suggesting 
that G2/M arrest induced by 1,25VD is mediated through GADD45. Further study 
showed that GADD45 mediates the effect of 1,25VD by decreasing cdc2 kinase activity. 
(c) hTERT, the catalytic subunit of telomerase, is identified as a primary target for 
 ix 
1,25VD. 1,25VD decreases telomerase activity and hTERT mRNA expression. The 
down-regulation of hTERT mRNA is due to decreased mRNA stability by 1,25VD, 
rather than decreased transcription of hTERT through VDRE. Clones stably transfected 
with hTERT showed higher telomerase activity and longer telomere length than parental 
cells. Moreover, hTERT clones resist 1,25VD-induced apoptosis and growth inhibition. 
In contrast to parental cells which do not recover from prolonged treatment with 1,25VD, 
hTERT clones re-grew rapidly after 1,25VD withdrawal. (d) We demonstrated that the 
1,25VD analogue EB1089 inhibits OCa cells in vitro and OCa xenograft in vivo without 
inducing hypercalcemia. We also demonstrated precursors for epithelial OCa express 
VDR and human primary ovarian surface epithelial cells respond to 1,25VD. Taken 
together, these results strongly suggest that 1,25VD analogues may be effective in the 
chemoprevention and chemotherapy of OCa. 
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INTRODUCTION 
 
 
Nuclear receptor superfamily  
The nuclear receptor superfamily consists of two classes of genes, nuclear 
hormone receptors and orphan receptors, which represent one of the most abundant 
classes of transcriptional regulators in animals (Robinson-Rechavi, 2003). It affects a 
wide variety of functions, including homeostasis, reproductive development, fatty acid 
metabolism and detoxification of foreign substances. The cognate ligands have been 
identified for nuclear hormone receptors, but for orphan receptors, the physiologically 
relevant ligand(s) remain unkown. The discovery of ligands for orphan receptors and 
additional receptors has become a very active research field. It has now been almost 20 
years since the isolation of cDNAs encoding the glucocorticoid, estrogen and thyroid 
receptors (Hollenberg, 1985; Green, 1986; Weinberger, 1986), which were the first 
several receptors identified. Novel signaling pathways controlled by nuclear receptors 
have opened up new aspects of nuclear receptors action with respect to homeostasis, 
reproduction, development and metabolism in various organisms. 
Nuclear receptors form a superfamily of phylogenetically related proteins, with 21 
genes in the complete genome of the fly Drosophila melanogaster, 48 in humans and, 
unexpectedly, more than 270 genes in the nematode worm Caenorhabditis elegans 
(nuclear receptor nomenclature committee,1999).              
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Nuclear hormone receptors are a class of molecules that function as both signal 
transducers and transcription factors.  The hormonal ligands for these receptors are 
hydrophobic molecules such as the sex steroids (androgens, estrogens, progesterone), 
glucocorticoids, thyroid hormones, mineralocorticoids, 1,25VD and retinoids (all-trans 
retinoic acid and 9-cis retinoic acid) etc. Other ligands, such as ecdysone, oxysterols, bile 
acids, leukotrienes and prostaglandins have been recently identified and characterized to 
have receptors that are structurally related to steroid receptor hormones and appear to act 
through similar mechanisms as the steroid receptors. Unlike the water-soluble peptide 
hormones and growth factors, which bind to cell surface receptors, the fat-soluble steroid 
hormones can pass through the lipid bilayer of the cell membrane and interact with their 
cognate receptors in the cell. These lipophilic hormones are potent regulators of 
development, cell differentiation, and organ physiology.  
Classification of nuclear receptors  
The nuclear receptor superfamily can be broadly divided into four classes (class I, 
II, III and IV), as proposed by Manglesdorf et al. (1995) based on their dimerization and 
DNA-binding properties (Fig. 1).  
Class I receptors include the known classical steroid hormone receptors, which 
function as ligand-induced homodimers and bind to palindromic response element. Class 
I receptors include receptors for steroids such as estrogens (ER), progesterones (PR), 
glucocorticoids (GR), mineralocorticoids (MR), and androgens (AR), These molecules 
have widespread effects on the development and control of the reproductive system 
(Beato, 1995; Cole, 1995; Couse, 1998 and 1999). 
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Fig. 1.  Structural and functional organization of nuclear receptors. 
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Fig. 1.  Structural and functional organization of nuclear receptors. The six domains 
(A-F) of nuclear receptors comprise regions of conserved function and sequences. All of 
nuclear receptors contain a central DNA binding domain (DBD), region C, which is the 
most highly conserved domain and includes two zinc finger modules. A ligand binding 
domain (LBD, region E) is located in the C-terminal half of the receptor, which contains 
activation function 2 (AF-2). Between the DBD and LBD is a hinge region (region D) 
that has variable length. In the amino terminus, the variable N-terminal region (A/B) 
contains transcriptional activation function 1 (AF-1). Some receptors also contain the F 
trail, the function of which is poorly understood. 
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Steroid receptors are believed to be synthesized in cytoplasms from single 
messenger RNAs (mRNAs). In contrast to other nuclear receptors, unliganded steroid 
receptors are associated with a large multi-protein complex of chaperones, including 
Hsp90 and the immunophilin Hsp56, which maintain the receptors in an inactive but 
conformation. When complexed with Hsp90, through amino acid residues at the 
receptor’s C-terminus, steroid receptors are unable to bind DNA (Pratt, 1993). 
The ER has two subtypes: ERa and ERb . Considerable divergence between ERa 
and ERb  is apparent in the N-terminus (18 % homology). ERa is the predominant 
subtype expressed in the major female organs such as ovary, uterus, vagina, mammary 
gland and certain areas of central nervous system especially in the hypothalamus. ERb  
exhibits a more limited expression patterns and is primarily detected in the ovary, 
prostate, testis, spleen, lung, hypothalamus and thymus (Couse, 1999; Kuiper, 1997). The 
differential distribution of each receptor in a certain tissues may reflect their distinct 
receptor functions. 
           The PR is unique among steroid receptors in that it is composed of two naturally 
occurring hormone-binding forms of proteins, A and B. The A isoform is an N-terminally 
truncated version of the full- length B isoform. The molecular weights of the human 
receptors as deduced from cDNA sequence are 98K and 86K, respectively. The A and B 
forms of the progesterone receptor differ in their ability to activate target genes and are 
regulated differently in various types of cells (Conneely, 2002). 
 The glucocorticoid receptor was the first transcription factor to be isolated and 
studied in detail (Muller, 1991). There are 3 isoforms of GR, a, b  and g. GRa modulates 
the expression of glucocorticoid-responsive genes by binding to a specific glucocorticoid 
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response element (GRE) DNA sequence. In contrast, GRb  and GRg inhibit the effects of 
hormone-activated GRa (Bamberger, 1995; Ray, 1996; Rivers, 1999), suggesting that 
GRb  and GRg may be a physiologically and pathophysiologically relevant endogenous 
inhibitor of glucocorticoid action and may participate in defining the sensitivity of tissues 
to glucocorticoids. 
 The MR is a 107 kD protein. MR was cloned by Arriza et al. (1987) and plays 
important roles in regulation of hydroelectrolytic homeostasis. MR activation by 
aldosterone raises renal salt reabsorption by increasing the activity of the epithelial 
sodium channel in the distal nephron. Although the distal nephron is recognized as the 
major site of action of mineralocorticoids, expression of MR in hippocampus, heart, and 
endothelium has suggested extrarenal activity (Le Menuet, 2000).  
The AR gene is more than 90 kb long and codes for a 76 kD protein. AR mediates 
the biological action of androgens, principally testosterone and 5 alpha-
dihydrotestosterone, that play critical roles in the development and growth of the male 
reproductive and nonreproductive systems. AR is found in a variety of tissues and 
changes throughout development, aging and malignant transformation (Chang, 1988; 
Lubahn, 1988).  
           Class II receptors heterodimerize with the receptor for 9-cis retinoic acid (RXR) 
and characteristically bind to direct repeats. Exclusive of the classical steroid hormones, 
this group includes almost all other known ligand-dependent receptors. The list of RXR-
dimer partners includes receptors for thyroid hormone (TR), vitamin D (VDR), retinoic 
acid (RAR), 9-cis retinoic acid (RXR), and ecdysone (EcR). These receptors are 
necessary for normal development, differentiation or organ morphogenesis (Kastner, 
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1995; Sambrook,1994). Moreover, its heterodimeric partner, RXRs, has been thought to 
exert multiple functions via their partner. The detection of an abnormal phenotype may 
raise the question as to which of these pathways has been affected.  
The class II receptors also include former orphan receptors for which endogenous 
ligands have been recently discovered, such as receptors for polyunsaturated long-chain 
fatty acids and their metabolites (peroxisome proliferator-activated receptors, PPARs), 
oxysterols (LXRs), bile acids (FXR), xenobiotics (xenobiotic receptor/pregnane X 
receptor, SXR/PXR and constitutive androstane receptor, CAR). These receptors have 
been “adopted” when they were shown to bind a physiological ligand (Chawla, 2001, 
Giguere, 1999, Blumberg B, 1998) and are now in the class II receptor category due to 
their ability to form heterodimers with RXR. Many of these “adopted” orphan receptors 
function as lipid sensors that respond to cellular lipid levels and elicit gene expression 
changes to ultimately protect cells from lipid overload. 
Three peroxisome proliferator-activated receptors (PPARs) isoforms have been 
characterized: PPARa, b/d and g. PPARs play a critical role in lipid and glucose 
homeostasis. Lately they have been shown to interfere with different steps of the 
inflammatory response by modulating the expression of chemokines, chemokine 
receptors and adhesion molecules in endothelial cells, smooth muscle cells, 
monocytes/macrophages and T cells (Blanquart, 2003).  
LXR are commonly known as cholesterol sensors that respond to elevated 
cholesterol concentrations. Oxysterols are natural ligands for LXR. LXR is abundantly 
expressed in the liver and other tissues that are associated with lipid metabolism (Peet, 
1998). Of particular interests are two xenobiotic receptors, SXR/PXR (human steroid 
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xenobiotic receptor/pregnane X receptor) and CAR (constitutive androstane receptor), 
which regulate the metabolic cascade of toxic endogenous lipids to protect the body from 
foreign chemicals. Whereas CAR mediates the response to phenobarbital- like inducers, 
SXR/PXR respond to many prescription drugs, steroids and toxic bile acids. These 
receptors seems to increase the clearance of foreign chemicals and provide an important 
feedforward loop for the xenosensors to initiate another round of signaling (Chawla, 
2001; Xie, 2001). 
Collectively, unlike the ‘classical nuclear hormone receptors’ of which ligands 
were well known before the receptors were cloned and the role of which was well 
established in reproduction and homeostasis via feedback regulation, aformentioned lipid 
sensors establish a new role for nuclear receptors in activating feedforward metabolic 
cascades that maintain lipid homeostasis by governing the transcription of genes involved 
in lipid metabolism, storage, transport and elimination.  
Most of the orphan receptors fall into the class III and IV categories. They 
represent a diverse and ancient component of the nuclear receptor superfamily, being 
found in nearly all animal species examined (Blumberg, 1998). Class III receptors, such 
as RXR, bind to direct repeats as homodimers. RXR is involved in the transduction of 
retinoid signaling pathway and it is activated in vitro by the vitamin A metabolite 9-cis 
retinoic acid but little is known of the natural activators of RXR. Although RXR forms 
(a, b , g) can function as homodimers, they also serve as the dimerization partner of other 
nuclear receptors including RAR, TR, VDR, PPARs, LXR, FXR. Thus, as a 
heterodimerization partner, RXR is involved in the regulation of multiple cellular 
pathways. Heterodimers PPAR-RXR, LXR-RXR, and FXR-RXR are permissive because 
 9 
both heterodimeric partners can bind their cognate ligands and induce transcription. 
Ligand binding by RXR has been demonstrated in the context of RAR and TR 
heterodimers, suggesting the possibility of permissiveness for RXR-RAR and TR-RXR 
heterodimers. Recently, allosteric modification of RXR by liganded VDR has been 
demonstrated. RXR acquires the holoreceptor conformation in the absence of its cognate 
ligand and gains the ability to recruit coactivators. These results provide evidence for 
RXR as a functionally active, nonsilent partner in 1,25VD-mediated RXR-VDR-
dependent gene expression (Bettoun, 2003). 
Class IV receptors typically bind to extended core sites as monomers, such as 
RevTRa (EAR1) and NGFI-b  which recognize the AGGTCA sequence without 
repetition.  
Although structurally related to the known receptors, no physiological ligands are 
known for these orphan receptors that are more numerous than receptors with known 
ligands (Blumberg, 1998). Taken together with the future identification of their definite 
ligand, orphan receptors will also provide an opportunity to identify potentially new 
functions in  physiology.  
Domain structure of nuclear receptors  
Despite their evolutionary and functional differences, members of the nuclear 
receptor superfamily generally share a similar structural organization. Typical nuclear 
receptor consists of multiple functionally distinct domains, including domains involved in 
DNA or ligand binding, dimerization, and transcriptional activation. Once they have 
bound their ligands, dimerized and achieved high-affinity association with specific 
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responsive elements in DNA, their transactivation domains function together at the 
molecular level, resulting in gene activation (Issa, 1998; Kumar, 1999).  
            The N-terminus of the nuclear receptor, A/B domain, has ligand- independent 
transactivation activity, termed activation function 1 (AF-1). The sequence and length of 
the A/B domain are highly variable among receptors (Weinberger, 1985). In addition, this 
region is the most frequent site of alternative splicing and secondary start sites, also 
contains a variety of kinase recognition sequences. It is thought that A/B domain may be 
responsible for the receptor-, species-, and cell type-specific effects, as well as promoter 
context-dependent properties of nuclear receptor transactivation. 
            Nuclear receptors are characterized by a central DNA-binding domain (DBD), 
which targets the receptor to specific DNA sequences known as hormone response 
elements. DBD, which is the most conserved region among various members of the 
superfamily, sets the nuclear receptors apart from other DNA-binding proteins. There are 
nine cysteine residues within the DBD that are strictly conserved throughout the 
superfamily of receptor proteins. The first eight cysteines in the N-terminus coordinate 
two zinc atoms to form the so-called zinc finger DNA-binding motifs that are responsible 
for high-affinity interaction with specific DNA sequences in the genomic region of 
hormone target genes. The first zinc finger contains the P (proximal)-box region, an alpha 
helix that is responsible for high affinity recognition of the “core half site” of the 
response element. Located within the second zinc finger, D (distal)-box, an alpha helix, 
determines the spacing between half-sites and mediates receptor dimerization. The 
second zinc finger contains a six-residue region, referred to as the T-box, which has been 
suggested to form a dimerization interface for the interaction with the RXR DBD. 
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Adjacent to the DBD is the D or hinge domain. This region has an poorly defined 
function. The D domain appears to allow for conformational changes in the protein 
structure following ligand binding. Also, this region may contain nuclear locolization 
signals and protein–protein interaction sites. 
The C-terminal half of the receptor encompasses the ligand-binding domain 
(LBD), which possesses the essential property of hormone recognition and ensures both 
specificity and selectivity of the physiologic response.  Although this domain is highly 
variable among family members, all nuclear receptors share a common structure of 10 to 
13 alpha helixes organized around a hydrophobic binding pocket. A ligand-dependent 
activation function (AF2) is located at the extreme C-terminus (helix-12). LBD also 
contains nuclear localization signals, dimerization motifs interaction surfaces for heat 
shock proteins, coregulators and for other transcription factors. The AF-2 domain 
provides an interactive surface fo r transcriptional corepressors and coactivators which 
links nuclear receptor activity with the preinitiation complexs (PIC). 
 Nuclear receptors act in three steps: repression, derepression and transcriptional 
activation (MacDonald, 2001). Repression is cha racteristic of the apo (unliganded)-
nuclear receptor, which recruits a corepressor complex that possesses histone deacetylase 
activity (HDAC). Derepression occurs following ligand binding, which dissociates this 
complex and recruits a first coactivator complex that has histone acetyltransferase (HAT) 
activity, resulting in chromatin condensation. In the third step, the HAT complex 
dissociates and a second coactivator complex is assembled (TRAP/DRIP/ARC), which is 
able to establish an interaction with the basal transcription machinery leading to 
transcriptional activation of the target gene. 
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Nuclear receptors may or may not contain a final domain at the C-terminus of the 
E domain, the F domain. The sequence of the F domain is extremely variable among 
different receptors and their function is largely unknown. 
Regulation of vitamin D receptor  
 VD and VDR 
VD was discovered nearly a century ago as the nutrient that prevented rickets, a 
devastating skeletal disease characterized by undermineralized bones (Brown, 1999). VD 
is a lipophilic hormone essential for normal bone structure and to maintain serum calcium 
levels. VD acts in concert with parathyroid hormone (PTH) to tightly regulate the 
concentration of serum calcium and phosphate, thereby assuring proper skele tal 
mineralization. In addition to its classic function in mineral homeostasis, the present 
concept of VD had been broadened to that of a hormone involved in a complex system 
that regulates proliferation and differentiation of a variety of cell types and tissues 
(Sutton, 2003) (Fig. 2).  
1,25VD is the biologically active form of VD. In the skin, 7-dehydrocholesterol is 
photo converted to pre-VD upon exposure to ultraviolet light, is then isomerized to VD. 
Subcequently, VD is metabolized in the liver to 25-hydroxy-VD3 and, primarily in the 
kidney, to 1,25VD. The major source of VD is through sunlight (UV-B)- induced 
photobiosythesis in the skin instead of food consumption (Sutton, 2003) (Fig. 2).  
VD action is mediated through the VDR, a member of class II nuclear receptors. 
VD-dependent stabilization of the VDR protein appears to occur in virtually all cell 
types. VDR heterodimerizes predominantly with RXR. Although VDR also forms 
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Fig. 2.  Metabolism and biological response of Vitamin D. 
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Fig. 2.  Metabolism and biological response of Vitamin D. Bioactive 1,25VD is 
generated by sequential hydroxylations of its precursor Vitamin D3 in the liver and 
kidney. PTH (parathyroid hormone) stimulates 1a-OHase expression in the kidney and 
promotes calcium mobilization from the bone and reabsorption from the kidney. 1,25VD, 
in turn, induces calcium absorption in the intestine and calcium release from the skeleton. 
The action of 1,25VD is mediated through VDR or non-genomic pathway. The distinct 
endocrine and paracrine/autocrine roles of 1,25VD are emphasized. The classic and 
nonclassic Vitamin D-responsive tissues are also listed.
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homodimers, these homodimers may not be transcriptionally active (Nishikawa, 1994; 
Issa, 1998).  
The human VDR (hVDR) gene has been localized to chromosome 12q13-14. The 
hVDR cDNA was cloned from a human jejunal poly(A)+ RNA library using avian VDR 
cDNA probe.  hVDR gene contains 11 exons that span more than 75kb (Miyamoto, 
1997). The noncoding 5-prime end of the VDR gene includes exons 1A, 1B, and 1C, 
while its translated product is encoded by 8 additional exons (2 to 9). Three mRNA 
isoforms are produced as a result of the differential splicing of exons 1B and 1C.  A 4.6 
kb human transcript, contains a 1281 nuc leotide open reading frame that codes for the 
full length VDR protein of 427 amino acids. The hVDR coding sequence is highly 
homologous to the avian, amphibian, mouse and rat sequences, particularly in the highly 
conserved nine cysteine residues of the DBD. Mammalian forms of VDR protein range in 
molecular weight between 52-60 by biochemical analysis, although the calculated 
molecular weight deduced from the amino acids sequence is 48.3 kD. The promoter of 
hVDR is GC-rich and does not contain an apparent TATA box, but has multiple Sp-1 
recognition sites and an array of putative binding sites for transcription factors.  
VDR shares structural homology with other nuclear receptors. However, AF1 is 
absent in the short A/B region at the N-terminus in VDR since removal of the A/B 
domain does not affect ligand binding, DNA binding or transactivation (Fig. 3). Two 
highly conserved zinc finger DNA binding motifs constitute the DBD, which also 
contains the nuclear localization signal. The D domain or hinge region regulates the 
receptor’s flexibility for conformational changes. Most of the natural mutations found in 
human VDR are located in the zinc finger region, resulting in defective DNA binding and  
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Fig. 3.  Molecular structure of the VDR. The DNA binding domain contains two Zinc 
finger structures. The ligand binding domain contains putative heterodimerization 
interfaces. Also shown are two phosphorylation sites at Ser-51and Ser-208. A TIFIIB-
interactive interface and a coactivator binding domain are also shown.  
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the most severe clinical phenotype of VD resistance (Haussler, 1998). The VDR LBD 
contains nine heptad repeats that form hydrophobic surfaces thought to act as 
dimerization interfaces. 
Coregulators of VDR 
In response to VD activation, VDR recruits multiple co-activators, including 
members of the p160 SRC family (Gill, 1998) and CBP/p300 family (Castillo, 1999) that 
either have or can or recruit histone acetyl transferase activity. These coactivators are 
essential for the formation of the initial transcription complex with RNA polymerase II.  
Recently, another coactivator complex has been identified as DRIP/TRAP complex 
(Rachez, 1999) that has no HAT activity and serves as a mediator between the VDR and 
RNA polymerase II complex (Pol II). DRIP/TRAP and SRC/p160 exist as distinct 
complexes but act cooperatively, as suggested in recent studies where both complexes 
were shown to act during the early stages of kerotinocyte differentiation. In the later 
stages of differentiation, DRIP/TRAP levels decrease and SRC/p160 assumes a 
predominant role (Oda, 2003). In addition to SRC and DRIP, NcoA-62/ski- interacting 
protein (skip) can augment VDR transcriptional activity (Baudino, 1998; MacDonald, 
2001). Skip lacks LXXLL motifs, selectively associates with the VDR-RXR through the 
LBD, but through a domain that is distinct from the Helix3-Helix5/Helix12 interaction 
surface. In contrast to coactivators, corepressors, NCoR (nuclear receptor corepressor) 
and SMRT (silencing mediator of retinoid and thyroid hormone receptors) have been 
found to associate with ligand unbound VDR, TR and RAR to repress ligand- induced 
transactivation functions.  
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Recently, Kitagawa et al. (2003) identified a multiprotein complex (WSTF 
Including Nucleosome Assembly Complex, WINAC); This is a novel ATP-dependent 
chromatin remodeling complex that directly interacts with VDR through the Williams 
syndrome transcription factor (WSTF). WINAC, like other SWI/SNF and 
ISWI/complexes, can reorganize the chromatin structure either by opening it to allow 
transcription or compacting it to repress gene expression. Manipulation of WSTF 
expression levels established that it is essential for VDR activity by either stimulating 
transcription from promoters regulated by positive response elements or repressing 
transcription from promoters containing negative response elements. Overexpression of 
WSTF can restore the impaired recruitment of VDR to VD-regulated promoters in 
fibroblasts obtained from Williams syndrome patients. This suggests that WINAC 
dysfunction contributes to Williams syndrome. This discovery has shed new light on the 
molecular mechanisms by which VDR controls gene expression with unexpected clinical 
implications (Belandia, 2003). 
Phosphorylation of VDR 
Hormone induced phosphorylation has been found in most nuclear receptors and 
may be involved in the regulation of receptor function. VDR contains two 
phosphorylation sites through which its activity can be modulated. Casein kinase 
positively regulates VDR activity while protein kinase C or protein kinase A negatively 
regulate it (Hsieh, 1991; Jurutka, 1996). VDR is phosphorylated by PKC at Ser-51 in 
vitro and in vivo, resulting in retardation of specific interactions of VDR with VDREs. 
Ser-208 is the preferred site phosphorylated by casein kinase II (CKII). Phosphorylation 
of Ser-51 or Ser-208 is not essential for VDR function but may reflect kinase specific 
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inputs that can be either positive or negative. The functional consequence of 
phosphorylation on VDR activity depend on both the cellular context and the signal 
transduction pathway or specific kinase involved. VDR phosphorylation represent a 
mechanism by which signals from the cell membrane in response to growth factor 
stimulation can modulate nuclear hormone receptor function. 
VDRE and VDR 
VDR forms heterodimers with RXR. Isoforms of the RXR (a,b ,g) serve as 
dimeric partners for VDR. In most cases, the VDR/RXR heterodimer binds VD response 
elements (VDREs) to mediate the biological activities of VD through transcriptional 
activation or repression of target genes containing VDREs in their regulatory sequence. 
Almost all VDREs were identified in the promoter region of VD-regulated genes (Issa, 
1998). 
Although there is considerable variations between natural VDREs, a consensus  
DR3 type VDRE can be defined as a direct repeat of  two six-base half elements of the 
sequence, separated by  a spacer of three nucleotides. The VDRE sequence directs the 
VDR-RXR heterodimer where RXR binds the 5’ half site and VDR occupies the 3’ half 
site (Haussler, 1998). The orientation and spacing of the response elements directs the 
polarity of heterodimer binding. The fifth nucleotide position of the 3’ half site is thought 
to be necessary for heterodimer binding. Although VDR-RXR complexes that interact 
with DR3 VDREs predominate the transcriptional response to 1,25VD, alternative routes 
appear to be possible both with respect of dimmer formation and target gene VDRE 
structure (direct repeat 6, DR6 and inverted repeat 9, IR9). The RXR dimerization 
surfaces on VDR are located in the first zinc finger and in a structural motif designated as 
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heptad repeats in the LBD. Asn37 in the P-box of the first zinc finger, Lys91 and Glu92 
situated in the T-box COOH terminal of the second zinc finger, and two of the heptad 
repeats within the LBD are critical in determining selective association between the VDR 
and its protein partner, RXR. Heterodimerization of the ligand-activated VDR with RXR 
induces a VDR conformation that is essential for VDR transactivating function (Brown, 
1999). VDR homodimers showed binding activity for DR6 type elements in both ligand-
dependent and independent manner, while the functional significance of a VDR 
homodimer is yet unclear.  
Several negatively regulated VDREs were also identified in some genes such as, 
avian and human PTH (Liu, 1996) and protein kinase A (PKA) inhibitor (Rowland-
Goldsmith, 1999).  Interestingly, by changing the two 3’-terminal bases GT of the avian 
PTH VDRE to the concensus CA, the VDRE reversed from a negative to a positive 
VDRE (Koszewski, 1999). 
Nongenomic effect of VD 
Most of the biological actions of VD are thought to occur through the nuclear 
VDR-mediated expression of target genes. Because these responses require transcription 
and translation of target genes, they are typically delayed by at least 30 min. However, 
more rapid effects (within seconds to minutes) in response to steroid hormones are also 
observed. For example, 1,25VD can stimulate the rapid formation of second messengers 
including ceramides, cAMP, inositols, calcium and to activate a variety of protein kinases 
such as protein kinase C, protein kinase A, raf, MAPK, and src kinases family 
(Gniadecki, 1996; Gniadecki, 1998; Marcinkowska, 1997). Although many in vitro 
studies have shown rapid effects by 1,25VD and numerous other steroids, the field is 
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hindered by the inablility to identify the putative membrane receptors that trigger these 
nongenomic effects. The study in VDR-knock out (VDRKO) mice showed that 
nongenomic effects of VD in osteoblasts are abrogated in the absence of nuclear VDR, 
suggesting that some nongenomic response require a functional nuclear VDR (Erben, 
2002).  VDRKO mice are important tools to decipher the molecular requirements of 
classical VDR that mediate the genomic and nonegenomic effects of 1,25VD in vivo. 
Biological actions of VD 
The genomic and nongenomic actions of VD produce a multitude of responses. 
VDR has been found in classical VD target organs such as the intestine, bone, kidney, 
and the parathyroid glands as well as a host of target tissues not involved in calcium 
homeostasis, such as skin, muscle, pancreas, reproductive organs, and hematopoietic, 
immune and nervous systems (Berger, 1988; Clemens, 1988). The diversity and the 
growing number of VD-regulated genes are a reflection of the pleiotropic effects of 
1,25VD on calcium and phosphate homeostasis, bone turnover, and proliferation and 
differentiation of a wide variety of cells, including keratinocytes, cancer cells and 
immune cells. Therefore the diversity and importance of VDR function goes far beyond 
mineral metabolism. Moreover, locally produced 1,25VD may serve as a paracrine 
modulator of cell growth and differentiation. 
            To investigate the functional role of VDR, Yoshizawa et al. (1997) generated 
mice deficient in VDR. VDRKO mice are viable and develop normally until the weaning 
period irrespective of reduced expression of VD target genes. Perhaps, the higher calcium 
content of murine milk, compared to human milk, keeps serum calcium normal, assuring 
normal growth of VDR-null mutant mice before weaning.  Not surprisingly, after 
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weaning, VDRKO mice displayed typical features of hereditary vitamin-D-resistant 
rickets (HVDRR), a rare genetic disorder caused by mutations in the VDR genes, with 
symptoms such as severe bone formation, hypocalcemia and alopecia. Although uterine 
hypoplasia, infertility and early lethality are not pronounced in patients with VD-
dependent rickets type II, possibly because of therapy with calcium supplements, most 
VDR-null mutant mice died within 15 weeks after birth; uterine hypoplasia with impaired 
folliculogenesis were observed. Uterine hypoplasia was caused by impaired estrogen 
synthesis in the mutant ovaries. However, the uterus of these animals responded normally 
to administration of estrogen. Male reproductive organs appeared normal in VDRKO 
mice. The fact that VDRKO mouse not only exhibits all features of human rickets, but 
also has marked growth retardation after weaning and uterine hypoplasia, implicates a 
role for VDR and calcium homeostasis during reproductive development and growth. 
Classical target tissues of VD related to calcium homeostatis are the intestines 
(calcium and phosphate absorption), kidney (phosphate and calcium reabsorption), 
parathyroid glands (suppression of PTH) and bone (osteoclasteogenesis, osteoblasts and 
mineralization).   Target genes in these organs with prominent VDR in their promoters 
are the calcium binding proteins calbindin D9K (intestine), calbindin D28K (kidney and 
other tissues), the non-collagenous bone-specific matrix protein osteocalcin and 
osteopontin (extracellular matrix protein in bone and other tissues) (Haussler, 1998). 
Serum 1,25VD is held constant in the normal state and is strictly regulated in response to 
factors controlling calcium homeostasis. 1,25 VD regulates its own metabolism and 
biosynthesis by stimulation of 24-hydroxylase activity and inhibition of 1a-hydroxylase 
(Sutton, 2003).   
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 In addition to its role in calcium homeostasis and bone metabolism, 1,25VD 
exhibits anti- inflammatory and immunosuppressive properties (Bouillon, 1995; Issa, 
1998). 1,25VD interacts with mature monocytes and macrophages, enhancing their 
immune function and improving host defense against both bacterial infection and tumor 
cell growth. In contrast to the stimulatory effects of the hormone on monocytes and 
macrophages, the principal action of 1,25VD in lymphocytes is as an immunosuppressive 
agent. It does so by decreasing both the rate of proliferation and the activity of T cells and 
B cells. 1,25VD and its analogues may prove beneficial as potential therapeutics in 
autoimmune diseases, such as psoriasis, multiple sclerosis, rheumatoid arthritis, diabetes 
and in transplantation. 
Effect of vitamin D in cancer  
Epidemiological data suggest that low VD levels increase the risk and mortality 
(Fig. 4) of prostate, breast and colon cancers (Waterhouse, 1976; Devasa, 1999). 1,25VD 
modulates cellular proliferation and differentiation of both normal and malignant cells.  
1,25VD and its synthetic analogues inhibit carcinogenesis in mouse skin (Chida, 1985; 
Webb, 1988), decrease the size of transplanted sarcomas, reduce lung metastasis in mice 
(Sato, 1982), suppress the growth of human colonic, prostate and pancreatic cancer 
xenografts in vivo (Eisman, 1987; Blutt, 2000; Colston, 1997), increase cell 
differentiation and decrease proliferation of leukemia (Dodd, 1983), breast (James, 1994) 
and prostate cancer (Blutt, 1997) cells. Studies in cancer cell lines have shown that 
1,25VD causes cancer cells to accumulate in the G1 phase of the cell cycle (Blutt, 1997), 
in the G2 phase (Eisman, 1989) or undergo apoptosis (Blutt, 2000; Simboli-Campbell, 
1996). The list of VD-induced proteins (Segaert, 1998) that pertain to cell growth and 
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Fig. 4. Ovarian cancer mortality rates in US, 1970-1994 (Devasa DJ et al. 1999, Atlas 
of cancer mortality in the United States. NIH publication No. 99-4564: pp 226-230). 
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differentiation is rapidly growing with HoxA10 (homeobox protein causing G1 arrest), 
Mad1 (differentiation-related transcriptional repressor), TNFa, insulin- like growth factor 
binding proteins 3 and 5, apolipoprotein D, tumor suppressors BRCA1 and E-cadherin. 
VDREs of numerous VD-responsive genes have been identified and characterized. Some 
VDREs are simple direct repeats while others are complex with often overlapping 
multimeric structures. The induction of DNA protein kinase links 1,25VD to DNA repair 
and cancer chemoprevention mechanisms.  
1,25VD and its synthetic analogues appear to exert their growth- inhibitory effects 
via regulation of cell cycle progression. Typically, treatment of cells with 1,25VD causes 
cell arrest in the G1 phase, resulting in a decreased number of cells in S phase, and 
increase in G0/G1. This change is associated with alterations in the expression of cell 
cycle regulators. Although a number of genes involved in cell cycle control, apoptosis 
and cell differentiation have been identified, the exact mechanisms underlying the growth 
regulatory actions of 1,25VD and its analogues have not been completely defined. 
In prostate model systems, VD has significant anti- tumor activity in vitro and in 
vivo (Blutt, 1997 and 2000; Johnson, 2002). The effect of 1,25VD is associated with an 
increase in cell cycle arrest, apoptosis, differentiation and modulation of growth factor 
receptors. VD induces G0/G1 arrest and modulates cyclin dependent kinase inhibitors, 
p21 and p27. VD induces PARP cleavage, increases bax/bcl-2 ratio, reduces levels of p-
MAPKs, and p-AKT, induces caspase-dependent MEK cleavage and up-regulation of 
MEKK-1, increases annexin V binding, which are markers of the apoptosis pathway 
(Johnson, 2002). Microarray studies in prostate cancer cells reveal many biologically 
relevant molecular targets of 1,25VD. For example, in LNCaP cells, 1,25VD causes 
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growth arrest through the induction of insulin- like growth factor binding protein-3 
(IGFBP3). These results provide a starting point for additional investigations to fully 
elucidate the mechanism of 1,25VD action in the prostate. 1,25VD can also significantly 
increase the efficacy of drug-mediated cytotoxicity. Phase I and II trials of 1,25VD either 
alone or in combination with carboplatin, paclitaxel or dexamethasone have been initiated 
in patients with prostate cancer. Data from these studies indicate that high-dose 1,25VD 
is feasible on an intermittent schedule, and provides proof of the concept that 1,25VD or 
its analogs are clinically effective (Johnson, 2002).    
1,25VD inhibits the proliferation and induces the differentiation of normal and 
leukemic myeloid cells into monocytes (Abe, 1981). 1,25VD regulates numerous genes 
such as c-fos, c-myc, IL-1, IL-6, TNFa, p21, p27 and Mad1, a pro-differentiating gene. 
These findings suggest that 1,25VD action on leukemic cells involves cell cycle control 
and differentiation. The response of hematopoietic cells to 1,25VD treatment depends on 
the cell type, differentiation state and dose of 1,25VD used. In most cell types, growth 
inhibition and maturation accompany each other. Both antiproliferative and 
differentiating effects of 1,25VD suggest a therapeutic role for the drug in hematological 
malignancies. 
In keratinocytes (Kitano, 1991), colonic adenocarcinoma cell lines (Scaglione-
Sewell, 2000) and squamous cancer cells (Hager, 2001), 1,25VD also blocks cell cycle 
progression in the G1 phase, preceded by the induction of the cyclin-dependent kinase 
inhibitors p21 and p27. This induction involves direct activation of p21 promoter through 
VDRE, as well as indirect mechanisms involving induction of growth inhibitory cytokine 
TGFb1 (transforming growth factor beta 1) and its type II receptor. In squamous cancer 
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cells, increased levels of CDK inhibitors prevent phosphorylation of the retinoblastoma 
protein and subsequent release of transcription factors of the E2F family. Therefore, 
upregulation of S-phase-related genes, such as the proto-oncogene c-myc, is inhibited. 
Non-classical positive VDREs were also demonstrated in the promoter of c- fos and 
phospholipase C g1, that both play a role in growth regulatory pathways. In human 
osteoblastic cells, cell cycle arrest at G0-G1 by a VD analogue is accompanied by 
hypophosphorylation of Rb followed by strong inhibition of Cdk2 activity (Maenpaa, 
2001). These effects also correlated with increased level of p27, decreased level of Cdk2 
and cyclin E, but p21 and cyclinD1 were not affected. G2/M arrested by VD or a VD 
analogue was also detected in Keratinocytes (Kobayashi, 1998).  
1,25VD has also been shown to induce apoptosis in breast (Welsh, 1994), prostate 
(Hsieh, 1997), colon (Diaz, 2000) and glioma (Baudet, 1996) cell lines. 1,25VD and its 
analogues induce apoptosis in MCF-7 breast cancer cells; induction of apoptosis was 
associated with upregulation of p53 and Bax. 1,25VD and its analogues are also capable 
of inducing apoptosis in T47-D breast cancer cells, which possess a mutated p53. It 
appears that induction of apoptosis is independent of p53 status (Mathiasen, 1999). This 
study suggests that sensitivity to 1,25VD-mediated apoptosis may be determined by the 
relative expression or subcellular distribution of pro- and anti-apoptotic members of the 
bcl-2 family rather than activation of any known caspase (Mathiasen, 1999). 
Upregulation of apoptosis-related proteins such as clusterin, cathepsin B and TGFb  has 
been reported in MCF-7 cells undergoing apoptosis in response to 1,25VD and its 
analogues (James, 1996).  In prostate cancer cells, 1,25VD-induced decreases in the 
levels of antiapoptotic proteins Bcl-2, Bcl-XL, and Mcl-1, BAG1L, XIAP, cIAP1, and 
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cIAP2 (without altering proapoptotic Bax and Bak) in association with increases in 
apoptosis (Guzey, 2002). Moreover, induction of apoptosis by 1,25VD was suppressed 
by overexpressing Bcl-2, a known blocker of cytochrome c release (Blutt, 2000; Guzey, 
2002). At this time the molecular mechanisms by which 1,25VD may induce apoptosis 
are not fully understood.  
Vitamin D analogue in cancer prevention and therapy 
Since the potential use of 1,25VD in the treatment or prevention of cancers is 
limited by the tendency of 1,25VD to cause hypercalcemia, recent research has focused 
on the development of analogues with less calcemic and/or greater antineoplastic activity 
than 1,25VD. Numerous VD analogues have been synthesized and many of them have 
modifications in the C-17 side chain of VD.  
Among them, Seocalcitol (EB1089) is the analog that has been widely 
administrated to patients in Europe in a Phase I trial resulting in stabilization of the 
disease in patients with advanced breast and colorectal cancer (Gulliford, 1998). EB1089 
contains a conjugated double bond system and is approximately 50 times more potent 
than 1,25VD in vitro, while the actions of EB1089 in calcium metabolism in vivo are 
markedly reduced. Phase II trials with hepatomas showed reduction in tumor dimensions 
in patients with an advanced bulky, solid tumor (Dalhoff, 2003). Their studies suggest 
that 1,25VD or its analogue have an effect in the treatment of multiple human cancers. 
           Either 1,25VD or EB1089 in combination with 9-cis RA act cooperatively to 
inhibit growth of breast, prostate, ovarian or small cell lung cancer cells (James, 1995; 
Guzey, 1998).  9-cis RA is a metabolite of vitamin A that has potent influences on cell 
differentiation, proliferation, homeostasis, and development. 1,25VD acts synergistically 
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with dexamethasone to suppress growth of breast, OCa and prostate cell lines (Johnson, 
2002; Saunders, 1995). These findings have important implications for the use of 
retinoids or dexamethasone with 1,25VD in cancer therapy. 1,25VD treatment enhances  
the sensitivity of prostate cancer cells to a number of anti-cancer drugs, such as paclitaxel 
(Taxol) and cisplatin (cis-diamminodichloroplatinum), indicating that VD compounds 
may be useful if used in combination with conventional chemotherapy (Johnson, 2002). 
  Vitamin D and ovarian cacer (OCa) 
Similar to breast and prostate cancers, OCa mortality and incident rates are lower 
in countries within 20 degrees of the equator (Waterhouse, 1976) where there are high 
amounts of sunlight. In the US women between the ages of 45-54 living in the North 
have 5 times the OCa mortality rate than women living in Southern states (Devasa, 1999; 
Waterhouse, 1987). The inverse correlation between sunlight exposure and OCa mortality 
indicates that in American women decreased synthesis of 1,25VD may contribute to OCa 
initiation and/or progression (Lefkowitz, 1994).  
OCa has the worst prognosis and remains the most challenging among 
gynecological malignancies, since it is not diagnosed at an early stage and has severely 
progressed when diagnosed. Although surgical dissection of tumors and intense 
chemotherapy is routinly used to treat OCa, severe drug resistance results in only 20-30% 
survival rates.   Poor response of advanced OCa to current treatments necessitates the 
development of novel therapeutic strategies to fight this deadly disease. In recent years 
studies have been initiated to develop synthetic VD analogs as therapeutic agents for a 
variety of human cancers including breast, prostate and colon cancers, while the similar 
studies in ovary are very limited.  
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VDR has been found in both normal and cancerous human ovarian cells by 
immunohistochemistry; 83.3% of normal surface epithelium shows weak to moderate 
VDR immunoreactivity. Moderate to strong nuclear immunoreactivity for VDR was 
detected in almost all ovarian carcinomas tested (Villena-Heinsen, 2002). VDR was also 
found in rat ovaries by immunohistochemistry (Johnson, 1996) and in hen ovaries by 
ligand-binding assays (Dokoh, 1983), indicating that ovarian cells can respond to VD. 
VDR expression in gynecologic neoplasms, including OCa (Ahonen, 2000; Saunders, 
1992; Villena-Heinsen, 2002), has also been described, indicating that VD could be an 
effective agent in OCa treatment and/or chemoprevention.  The presence of VDR was 
demonstrated in the ovary and the VD-induced decrease in cell number in CHO and 
OVCAR3 was also described. Specifically, Ahonen et al. (2000) showed that a 9-day 
treatment of OVCAR3 cells with 100 nM 1,25VD resulted in 73% inhibition of growth. 
However, the mechanism of VD action in OCa cells, as well as the potential of 1,25VD 
and its analogues in OCa treatment remains unknown.  
GADD45 and ovarian cancer 
The growth arrest and DNA damage- inducibe (GADD) gene GADD45 codes for 
a multifunctional protein (19 kD) that binds numerous  proteins and plays a role in cell 
cycle progression as well as the maintenance of genomic stability. Both genotoxic (i.e., 
UVR, IR, cisplatin, and adriamycin) and nongenotoxic stresses (i.e., apoptotic and/or 
growth- inhibitory cytokines, serum starvation) induce GADD45 activation. GADD45a 
(GADD45) belongs to the GADD45 family which also contains GADD45 beta and 
gamma. GADD45a is the only member that is induced by p53; the p53 binding site has 
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been identified in intron 3 (Hollander, 1993). p53- independent induction of GADD45 
may also be achieved depending on the insult.  
GADD45 interacts with the products of two other p53-regulated genes, p21 and 
PCNA (proliferating cell nuclear antigen) (Vairapandi, 1996; Smith, 1994). PCNA 
impedes Gadd45-mediated negative growth control (Vairapandi, 2000). Zhan et al. 
(1999) have shown that Gadd45, through its association with cdc2, appears to disrupt 
interactions between cdc2 and Cyclin B1 and thus may induce arrest at G2/M. 
 GADD45-null mice have increased sensitivity to dimethylbenzanthracene 
(DMBA)-induced carcinogenesis (Hollander, 2001). It is worth to note that in Gadd45a-
null mice, DMBA induces a dramatic  increase in female ovarian tumors compared to the 
wild type (Hollander, 2001). Therefore, GADD45 may protect the ovary from 
carcinogenesis, while the role of GADD45 in OCa is not well defined. Although the 
upregulation of GADD45 by 1,25VD has been found in squamous cancer cells (Akutsu, 
2001), the mechanism of the upregulation and the role of GADD45 in 1,25VD induced 
growth inhibition remain unknown.  
Telomerase and ovarian cancer 
The ends of chromosomes, the telomeres, are subject to progressive shortening in 
normal somatic cells, leading ultimately to irreversible growth arrest. In contrast, 
telomeres in all cancer cells are stabilized in length and effectively immortalized by the 
enzyme telomerase, which catalyzes the synthesis of telomeric DNA repeats. Telomerase 
is a ribonucleoprotein complex that is made up of three components: 1. RNA template-
human telomerase RNA (hTR) contains a sequence complementary to the telomeric 
TTAGGG repeat; Telomeres act as protective caps, stabilizing the chromosomes by 
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preventing their degradation and aberrant recombination during cell division.    2.  Protein 
component -human telomerase associated protein 1- (hTEP1). 3. Catalytic subunit, 
known as hTERT, which is a type of reverse transcriptase able to synthesize TTAGGG 
repeats from the RNA template. The cellular activity of telomerase is determined by the 
presence or absence of hTERT. All human somatic cells constitutively express hTR 
(Cech, 2004; Newbold, 2002).    
Telomerase is responsible for the replication of chromosome end structures and is 
strongly upregulated in most human cancers. RT-PCR analysis revealed that hTR and 
TP1 mRNA were expressed in more than 80% of OCa and even in normal ovaries. There 
was a significant correlation of telomerase activity with hTERT mRNA expression but 
not with TP1 or hTR. Repression of telomerase activity is associated with hTERT 
mRNA, but the expression of hTR and TP1 remained unchanged (Park, 1999; Kyo, 
1999). The rate- limiting step for telomerase activity seems to be the expression of the 
hTERT gene. The precise mechanism of how hTERT is regulated has not been elucidated 
yet. 
           It has been shown that OCa cells containing wild type hTERT readily produce 
tumors while cells with dominant negative hTERT failed to form tumor in nude mice. 
This studya confirms the hypothesis that inhibition of telomerase will decrease 
tumorigenicity of OCa cells in vivo and supports the concept that hTERT is a potential 
site for anti-cancer drug design for OCa (White, 2001).  The protective effect of 
telomerase from apoptosis has been proposed for human fibroblasts and neuron cells 
(Ren, 2001; Gorbunova, 2002; Fu, 2000). A study of epidermoid tumor cells indicated 
that telomerase inhibition in cells with short telomeres leads to chromosomal damage, 
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which in turn triggers apoptotic cell death (Zhang, 1999). These data indicated that 
inhibition of telomerase activity is a potential approach for the treatment of human 
malignancy. Until now, little is known about the mechanism and significance of 
telomerase repression by VD in solid tumors including OCa. We observed growth 
inhibition by VD in OCa cells. Consequently, the mechanism and role of telomerase in 
VD induced growth inhibition was investigated in OCa cells. 
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STUDY OBJECTIVES 
 
We hypothesize that 1,25VD through VDR-mediated gene regulation inhibits the 
development of OCa; We further hypothesize that 1,25VD and its synthetic analogues 
might be used for OCa prevention and therapy. Based on hypothesis, the study objectives 
are: 1. Determine the biological responses of OCa cells to 1,25VD treatment; 2. Examine 
molecular mechanism of 1,25VD action by identifying target genes which mediate the 
different biological response;  3. Test the antitumor activity of 1,25VD analogues in vitro 
and in vivo.  
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RESULTS  
The work presented here provides evidence that GADD45 and telomerase are 
regulated by 1,25VD and defines a mechanism for 1,25VD in OCa cells. Our studies 
identify GADD45 and hTERT as important mediators of the tumor-suppressing activity 
of 1,25VD in OCa cells. Our study also provides preclinical data indicating the 
effectiveness of synthetic 1,25VD analogues in OCa prevention and therapy. 
Effect of 1,25VD in OCa cells       
1.  1,25VD suppresses OCa cell growth and induces cell cycle arrest at G1/S 
and G2/M  
To better understand the molecular mechanism of 1,25VD action in OCa cells, we 
tested the response of OCa cells to 1,25VD in proliferation assays. Cells were treated 
with vehicle (ethanol, ETOH) or 10-7 M 1,25VD for 6 or 9 days and cell growth was 
determined by MTT assays. As shown in Figure 5, panel A, OVCAR3 cell growth 
decreased in the presence of 10-7 M 1,25VD in a time-dependent manner, confirming the 
sensitivity of OVCAR3 to VD (Saunders, 1992). Since cell growth was not significantly 
affected by 1,25VD at concentrations of 10-8 M or lower (data not shown), it appears that 
there is a threshold to the action of 1,25VD.  
 To determine the mechanism underlying the 1,25VD-induced growth suppression, 
OVCAR3 cells were treated with vehicle or 10-7 M 1,25VD for 9 days and analyzed by  
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Fig. 5.  1,25VD inhibits OCa cell growth and induces cell cycle arrest at G1/S and 
G2/M checkpoints. 
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Fig. 5.  1,25VD inhibits OCa cell growth and induces cell cycle arrest at G1/S and 
G2/M checkpoints. (A) Suppression of cell growth by 1,25VD. OVCAR3 cells were 
plated in 96 wells and treated with 10-7 M 1,25VD (VD) or ethanol (ETOH) as a vehicle. 
Cell numbers were determined by the MTT assay. Eight samples were analyzed for each 
data point, and the data were reproduced three times, *P<0.01 (versus ETOH treatment). 
(B) Induction of cell cycle arrest at G1/S and G2/M checkpoints by 1,25VD. OVCAR3 
cells were treated with ETOH or 10-7 M 1,25VD for 9 days.  Treated cells were subjected 
to flow cytometry analysis. Data were reproduced three times. The cell cycle profile of a 
representative experiment is shown. G2/M peak (red color) is indicated by the arrow. (C) 
Bar graphs show the average percentages of cells at G0/G1, S and G2/M in OVCAR3 
cells treated with 1,25VD or ETOH for 9 days, * P<0.05 (versus ETOH treatment). 
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flow cytometry.  Figure 5, panel B shows that 1,25VD decreased the percentage of cells 
in the S phase, which was accompanied by an accumulation of cells in G0/G1 and G2/M. 
This suggests that 1,25VD causes cell cycle arrest at both G1/S and G2/M checkpoints. 
The increase in G0/G1 was estimated as 13% while the percentage of cells at G2/M 
increased by 8% (Fig. 5C), suggesting that cell cycle arrest at both checkpoints 
contributed roughly equally to the growth-suppressing activity of 1,25VD. Contrary to 
drugs used in conventional cancer chemotherapy, inhibition of cancer cell growth by 
1,25VD is a chronic process, explaining why the effect on the cell cycle is modest and 
requires treatment for a longer time.   
2. 1,25VD induces apoptosis in OCa cells 
            To determine whether 1,25VD treatment induces apoptosis in OVCAR3 cells, 
OVCAR3 cells were treated with vehicle or 1,25VD for 9 days and fragmented DNA was 
detected by the Annexin V apoptosis assay kit. Apoptosis was induced to more than 60% 
in OVCAR3 cells after 9 days treatment of 1,25VD, as shown in Figure 6. 
3.  1,25VD-treated OVCAR3 cells recover slowly after 1,25VD withdrawal. 
           To determine whether changes induced by 1,25VD are sustainable, we tested 
whether growth inhibition of OVCAR3 cells by 1,25VD can be reversed by removal of 
the hormone. OVCAR3 cells are treated with 1,25VD for 9 days, and then 1,25VD was 
removed and cells were plated in 96 well plates with fresh medium. Cells were 
subsequently grown for an additional 12 days in the absence of the hormone. Consistent 
with studies  in prostate  cancer cells (Blutt, 2000),  Figure 7 demonstrated   that  
OVCAR3 cells  pretreated  with  1,25VD  recover  slowly  from  the  treatment  when  
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Fig. 6.  1,25VD induces apoptosis in OCa cells. (A) OVCAR3 cells were treated with 
ETOH or 10-7 M 1,25VD (VD) for 9 days. Apoptosis index was determined by DNA  
fragmentation assay and a representative profile is shown. (B) Bar graphs show 
percentage of apoptotic cells in two experiments. 
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Fig. 7.  OCa cells recover slowly after 1,25VD treatment. OVCAR3 cells were 
pretreated with 10-7 M 1,25VD (VD) or ETOH for 9 days. Recovery of treated cells was 
assessed at indicated times after plating pretreated cells in 96 well plates. Cell numbers 
were determined with the MTT assay. Eight samples were analyzed for each data point, 
and the data were reproduced three times. 
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1,25VD is removed from the medium compared with vehicle treatment. The poor 
recovery of OVCAR3 cells from 1,25VD treatment further confirmed that extensive 
growth inhibition was induced by 1,25VD.  
G2/M arrest by 1,25VD in OCa cells is mediated through the induction of 
GADD45 via an exonic enhancer 
To identify the genes that mediate the inhibitory effects of 1,25VD on cell cycle 
progression, a microarray analysis was performed to screen for genes that are 
differentially expressed in OCa cells treated with vehicle vs. 10-7 M 1,25VD. OVCAR3 
cells treated with 1,25VD showed a significant induction of the 1,25VD-dependent 24-
hydroxylase gene, a gene is known to be upregulated by 1,25VD. In OVCAR3 cells, 
1,25VD regulated genes encoded growth factors/modulators, cytokines, kinases and 
transcription factors. Some of them were implicated in cell cycle regulation and apoptosis 
(data not shown).  
GADD45 is a nuclear protein with well-known roles in G2 control and it has been 
shown to be upregulated by 1,25VD in our microarray analysis. In order to explore the 
molecular mechanism of 1,25VD-induced G2/M arrest, the regulation of GADD45 was 
investigated in OCa cells. 
1. GADD45 is a primary and immediate early response gene for 1,25VD in 
OCa cells 
 Among the many differentially expressed genes from the microarray experiment, 
GADD45 was one of the genes that were upregulated by 1,25VD (data not shown). Since 
GADD45 has a well-established role in cell cycle control (Wang, 1999; Zhan, 1999) in 
ovarian tumorigenesis (Hollander, 2001), we used Northern blots to confirm GADD45 
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regulation by 1,25VD. Compared to cells treated with vehicle, 10-7 M 1,25VD 
significantly increased GADD45 mRNA levels; 10-8 M 1,25VD caused a barely 
detectable increase (Fig. 8A), showing that 1,25VD induction of GADD45 mRNA is 
dose-dependent.  The induction was detectable as early as 2 hours following 1,25VD 
treatment with maximum induction detected at 8 hours (Fig. 8B), suggesting that 
GADD45 is an immediate early responsive gene for 1,25VD. Treatment for times longer 
than 8 hours maintained the induction but did not further enhance it. mRNA levels of 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were not affected by 1,25VD, 
showing some specificity for the effect of 1,25VD on GADD45. The stability of 
GADD45 mRNA, as measured in the presence of actinomycin D, an inhibitor of RNA 
synthesis, was not different between cells treated with vehicle and 1,25VD (Fig. 8C), 
suggesting that the regulation of GADD45 by 1,25VD is transcriptional. Although the 
fold- induction of GADD45 was decreased (Fig. 8D), it persisted in the presence of an 
inhibitor of protein synthesis, cycloheximide. This shows that GADD45 induction by 
1,25VD does not require new protein synthesis, thus identifying GADD45 as a primary 
1,25VD target gene in OCa cells. This is consistent with the data from squamous 
carcinoma cells (Prudencio, 2001; Akutsu, 2001).  
2. A novel VDRE in the 3’ untranslated region of GADD45 mRNA mediates 
the transcriptional up-regulation of GADD45 by 1,25VD 
 To define the specific DNA elements that mediate the induction of GADD45 by 
1,25VD, the genomic sequence of GADD45 was examined for the presence of putative 
VDREs. Based on similarity to the consensus VDRE sequence (Toell, 2000)  
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Fig. 8.  1,25VD increases transcription of GADD45 mRNA in OCa cells.  
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Fig. 8.  1,25VD increases transcription of GADD45 mRNA in OCa cells.  (A) Dose-
dependent induction of GADD45 mRNA by 1,25VD. Total RNA was isolated from 
OVCAR3 cells treated with ETOH or 1,25VD (VD) at indicated dosages for 24 h. 20 mg 
RNA was used for Northern blot analysis with radio- labeled GADD45 and GAPDH 
probes. (B) Time course of the induction of GADD45 mRNA by 1,25VD. OVCAR3 cells 
were treated with ETOH or 10-7 M 1,25VD for the indicated times. Total RNA was 
isolated and Northern blot was performed as in panel A. (C) Lack of 1,25VD effect on 
GADD45 mRNA stability. OVCAR3 cells were treated with ETOH or 10-7 M 1,25VD for 
24 h. The cells were washed and subsequently treated with 5 mg/ml actinomycin D 
(ActD) for the indicated times.  Northern blot analysis was performed as in panel A. The 
signals on the Northern blots were quantified using Scion image Beta 4.02 software. The 
GADD45 signal was normalized with the corresponding GAPDH signal and presented in 
the graph as percentage of the GADD45 mRNA level at time 0. (D) Effect of 
cycloheximide (CHX) on the induction of GADD45 mRNA by 1,25VD.  OVCAR3 cells 
were exposed to ETOH or 10-7 M 1,25VD for 24 h in the absence or presence of 25 mM 
CHX. Northern blot was performed as in panel A. The GADD45 signal was quantified 
and normalized with the corresponding GAPDH signal as in panel C and presented in the 
bar graph as fold induction. 
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and the VDRE sequence of known VD target genes, such as osteopontin (OPN) (Noda, 
1990) and osteocalcin (OC) (Morrison, 1989), five putative DR3-type VDREs were 
identified (Fig. 9A). Four were in introns, one in exon 4 but none in the 5’ promoter 
region.  
To test which of the five putative VDREs bind the receptors, gel mobility shift 
assays (EMSAs) were performed with recombinant VDR and RXR proteins.  As shown 
in Figure 9, panel B, our conditions allow the detection of a specific VDR/RXR complex 
with the OC VDRE. The complex is up-shifted by an RXR antibody and decreased by 
excess cold OC probe (upper panel).  Under the same conditions, all putative VDREs 
except VDRE-C bound RXR/VDR with an affinity comparable to OC VDRE (Fig. 9B, 
lower panel). The binding is specific for the VDR/RXR heterodimer since neither RXR 
nor VDR alone formed a detectable complex with the VDRE probes. The VDREs were 
displaced from the complexes with an excess amount of cold OC VDRE but were not 
affected by the putative VDRE-C that did not bind VDR/RXR (Fig. 9C). This shows that 
the binding is specific. The RXR antibody up-shifted the complex while a non-related 
antibody did not, confirming the presence of RXR in the complex.   
 To determine whether VDREs binding the receptors in OVCAR3 cells mediate 
the induction of GADD45 by 1,25VD, a reporter gene was constructed with a 2.6 kb 
genomic DNA fragment of GADD45 containing all the putative VDREs located 
upstream of SV40 promoter and the cDNA of firefly luciferase gene (Fig. 10A). In 
OVCAR3 cells transiently transfected with this reporter, 1,25VD induced the luciferase 
activity in a dose (Fig. 10B) and time dependent manner (Fig. 10C).   
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Fig. 9.  Multiple putative VDREs are present in GADD45 genome, which interact 
with VDR/RXR in vitro. 
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Fig. 9.  Multiple putative VDREs are present in GADD45 genome, which interact 
with VDR/RXR in vitro. 
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Fig. 9.  Multiple putative VDREs are present in GADD45 genome, which interact 
with VDR/RXR in vitro. (A) Schematic representation of the human GADD45 genome 
and the position of the putative VDREs. The sequences of consensus DR3, mouse OPN 
(mOPN) VDRE, human OC (hOC) VDRE and the five putative GADD45 VDREs are 
listed. Hexameric VDRE half sites are shown in bold capital letters. The 3-bp space is 
shown in small letters. Deviations from the consensus sequence RGKTSA are underlined. 
(B) In vitro interaction of VDR/RXR heterodimer with putative GADD45 VDREs. 
EMSAs were performed in the presence of 10-7 M 1,25VD using hOC (upper panel) or 
putative GADD45 (lower panel) VDRE probes. Pre- incubation with 2 mg anti-RXRb  
(RXR-Ab) or 100-fold molar excess of cold hOC VDRE (Cold-hOC) was performed for 
the super-shift and competition experiments, respectively. (C) Specificity of the 
interaction between VDR/RXR heterodimer and the putative GADD45 VDREs. EMSAs 
were performed as in panel B. Specificity of the interaction was demonstrated by 
competition with 100-fold molar excess of unlabeled hOC VDRE oligos as a specific 
competitor and the lack of competition with VDRE-C oligos as nonspecific competitor. 2 
mg anti-Flag M2 monoclonal antibody was used as a non-specific antibody control for the 
super-shifting with anti-RXR antibody.  
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Fig. 10.  1,25VD induces GADD45 reporter activity through endogenous receptors 
in OCa cells. 
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Fig. 10.  1,25VD induces GADD45 reporter activity through endogenous receptors 
in OCa cells. (A) Schematic representation of GADDLuc construct. (B) Dose-dependent 
induction of GADD45 VDRE reporter activity by 1,25VD. OVCAR3 cells were 
transfected with 0.2 mg GADDLuc, 0.05 mg pCMVgal, 0.05 mg p91023B-VDR and 0.05 
mg pCMX-RXRb  and treated with ETOH or 1,25VD at the indicated concentrations.  
Luciferase activity was determined and normalized with cognate b-gal activity. Each data 
point was analyzed in duplicate and reproduced three times. (C) Time-dependent 
induction of GADDLuc luciferase activity by 1,25VD. OVCAR3 cells were transfected 
as in panel A and treated with ETOH or 10-7 M 1,25VD for the indicated times. 
Luciferase activity was determined as in panel B.  (D) Induction of reporter activity by 
1,25VD in cells stably transfected with the GADDLuc. OVCAR3 cells stably transfected 
with GADD45 reporter were transfected with 0.05 mg pCMVgal, 0.05 mg p91023B-VDR 
and 0.05 mg pCMX-RXRb  and treated with ETOH or 10-7 M 1,25VD for 36 h. Luciferase 
activity from two stable clones was determined and shown as fold induction. (E) 
Endogenous VDR/RXR in OVCAR3 cells is sufficient for 1,25VD induction of 
GADD45 reporter. OVCAR3 cells were transfected with GADDLuc and pCMVgal with 
or without p91023B-VDR (VDR) and pCMX-RXRb  (RXR). The total amount of plasmid 
DNA was balanced with empty vectors. Luciferase activity was determined as in panel B. 
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This induction was also detected in OVCAR3 cells in which the reporter was stably 
integrated into the genome (Fig. 10D), showing that it is not an artifact of the transient 
transfection. Expression of additional VDR, RXR or both did not further increase the 
induction in OVCAR3 cells (Fig. 10E), suggesting that endogenous RXR and VDR in 
OVCAR3 cells are sufficient.  
To test whether 1,25VD regulates the GADD45 reporter through VDR, the 
activation of the reporter was tested in HeLa cells that lack functional VDR. As shown in 
Figure 11, panel A, 1,25VD did not induce the activity of a known VDR reporter, p23, 
that was constructed with the promoter of 24-hydroxylase (Arbour, 1998). The induction 
of the p23 reporter was restored by the ectopic expression of VDR in HeLa cells. Similar 
to the p23 reporter, 1,25VD did not cause measurable induction of luciferase activity in 
the GADD45 reporter in HeLa cells (Fig. 11B). Co-transfection with VDR restored the 
1,25VD induction in a manner that is dependent on the dose of the transfected receptor 
(Fig. 11B). Transfection with RXR alone did not affect reporter activity but its co-
transfection with VDR enhanced the induction compared to cells transfected with VDR 
alone.  Similar to the results with OVCAR3 cells, 1,25VD induced reporter activity in 
HeLa cells in a dose and time dependent manner after receptor transfection (data not 
shown). These experiments demonstrate that the regulation of the reporter is VDR-
dependent and involves the RXR. 
 To determine which of the putative VDREs is functional, OVCAR3 cells were 
transfected with reporter constructs where VDREs, either individually or in  
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Fig. 11.  Induction of GADD45 reporter activity by 1,25VD is VDR-dependent. (A) 
The lack of functional VDR in Hela cells. Cells were transfected with 0.2 ?mg p23 and 
pCMVgal with or without p91023B-VDR. Transfected cells were treated and luciferase 
activity was determined as in Fig. 10B.  (B) VDR-dependent induction of GADD45 
reporter activity by 1,25VD.  Hela cells were transfected with GADDLuc and pCMVgal 
with the indicated amounts of p91023B-VDR, pCMX-RXRb  or both. The total amount of 
plasmid DNA was balanced with empty vectors. Luciferase activity was determined as in 
Fig. 10B. 
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combination, were deleted or mutated by altering key nucleotides known to be essential 
for receptor interaction. As shown in Figure 12, panel A, deletion of the VDRE-A or 
VDRE-A plus VDRE-B region did not affect 1,25VD induction. Deletion into the 
VDRE-D region caused a significant decrease while further deletion into the VDRE-E 
region eliminated 1,25VD induction. These analyses suggest that regions around VDRE-
D and VDRE-E are essential for 1,25VD regulation of GADD45.  
Site-directed mutation in VDRE-E eliminated the induction, while single or 
multiple mutations of key nucleotides in the intronic VDREs had no effect. This suggests 
that only VDRE-E is essential for the induction. This conclusion is consistent with the 
lack of VD induction in mutant reporters containing only VDRE-D or both VDRE-A and 
VDRE-B (Fig. 12A). It is also consistent with the induction of the reporter that contains 
only VDRE-E (Luc3) and with the loss of this induction by site-directed mutation of 
VDRE-E (MTELuc3) (Fig. 12A).  
Individual mutation of the first two VDREs or combined mutation of all first three 
VDREs actually increased VD induction, indicating that some VDREs may function in a 
negative fashion. The deletion of the VDRE-D region, not the mutation of the VDRE-D 
sequence, caused a decrease in VD induction suggesting that DNA elements in the 
VDRE-D region for transcription factors other than VDR may cooperate with VDR/RXR 
binding to VDRE-E to mediate the up-regulation of GADD45. The lack of a VD effect on 
the activity of pGL3-basic, pGL3-promoter and the pGL3-control vectors showed that the 
regulation of the reporters by 1,25VD is specific to the GADD45 sequence.  
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Fig. 12.  The VDRE in the fourth exon of GADD45 genome is the functional VDRE 
that mediates the transcriptional induction of GADD45 by 1,25VD in OCa cells. 
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Fig. 12.  The VDRE in the fourth exon of GADD45 genome is the functional VDRE 
that mediates the transcriptional induction of GADD45 by 1,25VD in OCa cells. (A) 
Mutational analysis of the GADD45 reporter. OVCAR3 cells were transfected with 0.2 
mg of the reporter constructs together with pCMVgal, p91023B-VDR and pCMX-RXRb  
and treated with ETOH or 10-7 M 1,25VD for 36 h. Luciferase activity was determined as 
in Fig. 10B and shown on the right. Schematic representation of the different reporter 
constructs is shown on the left.  pGL3-basic, pGL3-promoter and pGL3-control vectors 
were used as controls. (B) ChIP assays. Soluble chromatin was prepared from OVCAR3 
cells treated with ETOH or 10-7 M 1,25VD for 60 min. ChIP assays were performed with 
control (rat IgG) or anti-VDR antibody. The mock control is performed with 
immunoprecipitates from buffer that contains no soluble chromatin from OVCAR3 cells. 
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To demonstrate that the VDRE-E interacts with VDR in vivo, OVCAR3 cells  
were treated with or without 1,25VD and ChIP assays were performed with anti-VDR 
antibodies (Fig. 12B). From soluble chromatin prepared from OVCAR3 cells treated with 
1,25VD, the anti-VDR antibody precipitated GADD45 DNA fragments containing the 
VDRE-E but not the promoter regions. The specificity of the ChIP assay was 
demonstrated by the lack of VDRE-E DNA in the mock as well as in the  
immunoprecipitates of rat IgG control. The data shows that VDR is recruited to the 
VDRE-E in vivo.  More importantly, the recruitment of VDR to the response element is 
apparently ligand-dependent since the anti-VDR antibody did not precipitate GADD45 
DNA fragments from soluble chromatin prepared from cells treated with the vehicle.  
3.  Upregulation of GADD45 protein is required for the hormone-induced 
cell cycle arrest at the G2/M but not the G1/S checkpoint  
Our studies have established GADD45 as one of the immediate early response 
genes for 1,25VD, but questions remain whether regulation at the RNA level extends to 
the protein level and whether GADD45 mediates the growth-suppressing activity of 
1,25VD in OCa cells. To address these questions, OVCAR3 cells were treated with 
1,25VD for up to 6 days and GADD45 protein expression was examined by 
immunoblotting. As shown in Figure 13, panel A, 1,25VD increased the level of 
GADD45 protein in a time dependent manner in OVCAR3 cells whereas the level of b-
actin remained constant during treatment. Compared to the data on GADD45 mRNA 
(Fig. 8B), 1,25VD-induced accumulation of GADD45 protein is a much slower process. 
This suggests the presence of additional regulations for GADD45 expression at post-
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transcriptional steps. The slower accumulation of GADD45 protein in response to 
1,25VD may explain why the hormonal effect on the cell cycle requires longer treatment.   
To test whether GADD45 mediates the inhibitory effect of 1,25VD on OCa cell 
cycle progression, OVCAR3 cells were stably transfected with an expression vector 
containing GADD45 cDNA in the anti-sense orientation (Zhan, 1994) or an empty 
vector. Immunoblot analysis of GADD45 was used to select stable clones with 
significantly reduced level of GADD45 protein by the anti-sense GADD45 as compared 
to the control clones (Fig. 13B). Although the anti-sense GADD45 did not completely 
eliminate GADD45 protein (Fig. 13B), it decreased the expression of GADD45 protein in 
the presence of 1,25VD to a level lower than basal level of control clones (Fig. 13B). In 
other words, the anti-sense clones represent a functional “knock out” of GADD45 in 
terms of VD induction. 
Flow cytometry showed that a decrease of GADD45 protein in the anti-sense 
clones was associated with an increase of the proportion of cells in G2/M phase and a 
decrease of those in S phase (Figs. 13C and 13D). In the control clones, 1,25VD 
decreased the percentage of cells in S phase and increased the cells in G0/G1 and G2/M, 
showing that the hormone induced a similar cell cycle arrest at both G1/S and G2/M 
transitions similar to that in the parental OVCAR3 cells (Figs.5B and 5C). In the anti-
sense clones, 1,25VD-induced G2/M accumulation was blocked whereas 1,25VD-
induced decrease in S phase and increase in G0/G1 still occurred (Figs. 13C and 13D). 
The data strongly suggest that GADD45 mediates the  
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Fig. 13. Anti-sense GADD45 blocks 1,25VD-induced cell cycle arrest at G2/M, but 
not G1/S checkpoint. 
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Fig. 13. Anti-sense GADD45 blocks 1,25VD-induced cell cycle arrest at G2/M, but 
not G1/S checkpoint. (A) Induction of GADD45 protein expression by 1,25VD in VD-
sensitive human ovarian cancer cells. OVCAR3 cells were treated with ETOH or 10-7 M 
1,25VD for indicated times and the level of GADD45 protein was analyzed by 
immunoblotting. Hela cells transfected with pCMV45 plasmid was included as a positive 
control. b-Actin was used to show the equal amount of total protein is present in each 
lane. (B) Suppression of GADD45 protein expression by stable expression of GADD45 
anti-sense cDNA. OVCAR3 cells stably transfected with control vector (Vector-
OVCAR3) or the anti-sense cDNA of GADD45 (AS45-OVCAR3) were treated with 
ETOH or 10-7 M 1,25VD for 24 h. The level of GADD45 and b-actin protein was 
determined as (A).  (C) Abrogation of 1,25VD-induced G2/M arrest in AS45-OVCAR3 
clones. Vector-OVCAR3 and AS45-OVCAR3 clones were treated with ETOH or 10-7 M 
1,25VD for 9 days. Cell cycle distribution was determined by flow cytometry. Three 
independent experiments were performed and the profile of a representative experiment 
is shown. G2/M peak is indicated by arrow.  (D) Bar graphs show percentage of cells at 
G2/M, G0/G1, and S phases. Each data point was analyzed in duplicate, *P<0.05; 
#P>0.05 (versus ETOH treatment). 
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inhibitory effect of 1,25VD on the G2/M transition in OVCAR3 cells. Similar to the data 
in colon cancer cells (Wang, 1999), the two untreated anti-sense GADD45 clones had 
slightly increased G0/G1 and G2/M fractions and slightly lower S fractions, compared 
with vector-control OVCAR3 cells. 
To firmly establish GADD45 as the mediator for the 1,25VD-induced cell cycle 
arrest at the G2/M transition, we tested the effect of 1,25VD on the cell cycle progression 
of mouse embryo fibroblasts (MEFs) established from either wild type or GADD45-null 
mice (Hollander, 1999). Both MEFs expressed similar levels of VDR protein as 
determined on immunoblots (Fig. 14A).  It is known that the MEFs from this strain of 
mice are a mixture of diploid and tetraploid cells (Hollander, 1999). This complicates the 
flow cytometry analysis of diploid cells, largely due to the inability to distinguish diploid 
cells at G2/M from tetraploid cells at G0/G1 phases. Therefore, we compared the changes 
induced by 1,25VD in the cell cycle distribution of tetraploid cells. As shown in Figure 
14, panels B and C, 1,25VD induced a consistent increase in the percentage of cells in 
G2/M and a decrease of that in S phase of wild type MEFs, although the magnitude of the 
response was less than in OVCAR3 cells. In GADD45-null MEFs, no induction of G2/M 
arrest by 1,25VD was observed, confirming the conclusion reached in OVCAR3 cells 
with the anti-sense approach that GADD45 is required for 1,25VD-induced cell cycle 
arrest at the G2/M transition. In the wild type and GADD45-null MEFs, 1,25VD did not 
induce G1/S arrest (data not shown). Since G1/S arrest by 1,25VD was observed in the 
MEFs derived from another strain of mice (unpublished data for a separate  
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Fig. 14.  1,25VD induces G2/M arrest in wild type but not in GADD45-null MEFs. 
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Fig. 14.  1,25VD induces G2/M arrest in wild type but not in GADD45-null MEFs. 
(A) Expression of VDR protein in wild type (WT) and GADD45-null MEFs. The level of 
VDR protein was determined by immunoblotting with anti-VDR antibody and equal 
loading was shown by immunoblotting with anti-b-actin antibody. (B) Induction of G2/M 
arrest in WT but not GADD45-null MEFs by 1,25VD. WT and GADD45-null MEFs 
were treated with ETOH or 10-7 M 1,25VD for 9 days. The cells were subjected to flow 
cytometry analysis. Three independent experiments were performed and the profile of a 
representative experiment is shown. The G2/M peak for tetraploid cells is indicated by 
the arrow. (C) Bar graph show the percentage of tetraploid cells at G2/M. Each data point 
was analyzed in duplicate, *P<0.01 (versus ETOH treatment). 
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Fig. 15.  1,25VD decreases cdc2 kinase activity in OVCAR3 transfected with control 
vector but not in cells stably transfected with the anti-sense cDNA of GADD45. 
Vector-OVCAR3 and AS45-OVCAR3 cells were treated with ETOH or 10-7 M 1,25VD 
(VD) for 9 days. Cellular extracts were immunoprecipitated with anti-cyclin B1 antibody. 
The activity of cdc2 was assayed using Histone H1 as a substrate.  The level of cdc2 and 
cyclin B1 protein was determined by immunoblotting. b-Actin blot was included to show 
the equal loading. 
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study in our lab), the response to 1,25VD appears to vary among MEFs from different 
strains. 
4. GADD45 mediates 1,25VD-induced decrease in cdc2 kinase activity in 
OCa cells 
It is well established that the G2/M transition of mammalian cells is controlled by 
the M phase promoting factor, a heterodimeric complex between cdc2 and cyclin B. 
Studies in recent years suggest that GADD45 may directly regulate the activation of cdc2 
kinase (Zhan, 1999). Therefore, the effect of 1,25VD on cdc2 kinase activity in control 
and GADD45 anti-sense clones was measured by in vitro immunocomplex kinase assays. 
As shown in Figure 15, 1,25VD decreased the kinase activity of cdc2 in the control clone. 
In the GADD45 anti-sense clones, there is an increase in cdc2 kinase activity (Fig. 15), 
presumably due to the decrease in the level of GADD45 protein. More importantly, 
1,25VD did not decrease the activity to a level below the basal activity of control clones. 
Immunoblot analysis showed that 1,25VD decreased the level of cyclin B protein and that 
the decrease was not observed in the anti-sense clones (Fig. 15), suggesting that 
GADD45 mediates the VD effect on cdc2 activity by regulating the cyclin B level in OCa 
cells. The data clearly suggest that G2/M arrest induced by 1,25VD in OCa cells is 
mediated through GADD45 and the subsequent decrease in cdc2 kinase activity.  
Collectively, our data demonstrated that G2/M arrest by 1,25VD in OCa was 
mediated through the induction of GADD45 via an exonic enhancer. Next, to further 
demonstrate the mechanism of 1,25VD induced growth inhibition, we investigated the 
regulation of telomerase by 1,25VD. 
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1,25VD-induced apoptosis   is mediated by destabilization of hTERT mRNA  
and  a decrease  in telomerase activity 
 Telomerase activity is increased in most human cancers. It has been shown that 
1,25VD reduced telomerase activity in HL-60 human acute myeloblastic leukemia cells 
correlated with 1,25VD-induced differentiation (Xu, 1996). In an effort to understand the 
mechanism underlying 1,25VD induced apoptosis, our study provides evidence that 
telomerase is decreased by 1,25VD and its decrease is responsible for the apoptosis 
induced by 1,25VD. 
1.   1,25VD down-regulates telomerase activity in OCa cells 
 
Cells undergoing apoptosis are associated with the decrease in telomerase activity 
(Saretzki, 2003). As shown in Figure 6, apoptosis was induced more than 3-fold in 
OVCAR3 cells by 1.25VD. To fully understand the role of 1,25VD in OCa cells and 
determine telomerase function in 1,25VD-induced apoptosis, telomerase activity was 
determined in OVCAR3 cells using PCR-based telomeric repeat amplification protocol 
(PCR-TRAP) assay.  OVCAR3 cells constitutively expressed significant telomerase 
activity and 1,25VD decreased telomerase activity in a time-dependent manner (Fig. 16). 
PCR-TRAP assay performed with various ammounts of protein indicated that 200 ng of 
protein extract provided a quantitative and reproducible assay for telomerase activity on 
OVCAR3 cells (data not shown). The activity was not detectable when the extract was 
heated to 65oC to abolish the enzymatic activity of protein components of telomerase. 
These results confirmed the specificity of the telomerase signal measured in this assay. 
Within 3 days of 1,25VD treatment, telomerase activity remained ~ 50% of the control, 
whereas at day 6 and day 9  
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Fig. 16.  1,25VD down-regulates telomerase activity in OCa cells. The OVCAR3 cells 
were treated with 10-7 M 1,25VD for the indicated times. The protein was extracted and 
subjected to the PCR-TRAP assay, as described in Materials and Methods 
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Fig. 17.  1,25VD down-regulates hTERT mRNA expression in OCa cells. 
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Fig. 17.  1,25VD down-regulates hTERT mRNA expression in OCa cells. Dose-
dependent inhibition of hTERT mRNA by 1,25VD. Total RNA was isolated from 
OVCAR3 cells treated with ETOH or 10-7 M 1,25VD for indicated times. 2 mg RNA was 
used for RT-PCR analysis (A) and Real-time PCR analysis (B) as described in Materials 
and Methods. (C) Effect of cycloheximide (CHX) on the inhibition of hTERT mRNA by 
1,25VD.  OVCAR3 cells were exposed to ETOH or 10-7 M 1,25VD for 6 days in the 
absence or presence of CHX at the indicated concentrations. RT-PCR was performed as 
shown on panel A. RNA purified from pBABhTERT transfected OVCAR3 cells as 
positive control. RT reaction without reverse transcriptase was the negative control.  
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telomerase activity fell to only 15% of the control cell. Combined with data in Figure 5, 
these experiments showed that inhibition of telomerase activity by 1,25VD was 
correlated with the growth inhibition and apoptosis induced by 1,25VD. These data 
supported that 1,25VD induced apoptosis was associated with decreased telomerase 
activity. 
2.  hTERT is a VD-targeted gene in OCa cells 
            To investigate the mechanism of VD action on telomerase, RT-PCR was used to 
determine the mRNA level of hTERT. Compared to cells treated with vehicle, 10-7 M 
1,25VD decreased mRNA levels of hTERT in a time-dependent manner (Fig. 17A). 
Consistent with decreased telomerase activity by 1,25VD, inhibition began after 1 day of 
1,25VD treatment, with further decrease detected after treatment for 3 , 6 and 9 days (Fig. 
17A). The mRNA levels of GAPDH were not affected by 1,25VD, showing some 
specificity for 1,25VD.  In order to quantitatively determine the decrease of hTERT  
mRNA,  real-time PCR was performed using total RNA purified from OVCAR3 cells 
treated with vehicle or 10-7 M 1,25VD. The results confirmed the decrease of hTERT 
mRNA after 3 days of 1,25VD treatment and further decrease after 9 days of treatment 
(Fig. 17B). These data indicate that the mechanism of telomerase down-regulation 
involves the change in the mRNA of hTERT. The down-regulation of hTERT mRNA by 
1,25VD persisted in the presence of cycloheximide, an inhibitor of protein synthesis (Fig. 
17C), suggesting that hTERT inhibition by 1,25VD does not require new protein 
synthesis, and that hTERT is a primary responsive gene for 1,25VD in OCa cells. 
            
 70 
 
 
 
Fig. 18.   Putative hTERT VDRE specifically binds to VDR/RXR heterodimer. 
EMSAs were performed in the presence of 10-7 M 1,25VD using putative hTERT VDRE 
probes. Pre- incubation with 2 mg anti-RXRb (RXR-Ab) or 100-fold molar excess of cold 
hOC VDRE (Cold-hOC) was performed for the super-shift and competition experiments, 
respectively. Specificity of the interaction was demonstrated by competition with 100-
fold molar excess of unlabeled hOC VDRE oligos as a specific competitor and the lack of 
competition with Gadd45 VDRE-C oligos as nonspecific competitor. 2 mg anti-Flag M2 
monoclonal antibody was used as a non-specific antibody control for the super-shifting 
with anti-RXR antibody.  
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Fig. 19.  The putative VDRE is not a functional VDRE in OVCAR3 cells. The 
OVCAR3 cells were transfected with 0.2 mg pGL3-3328Luc (A, B) together with 0.1 mg 
CMVbgal and 0.1 mg VDR. The transfected cells were treated with   10-7 M 1,25VD, 10-6 
M 9-cis RA or ETOH as indicated. Luciferase activity was determined and normalized by  
bgal activity. (C) 3328Luc was stably transfected into OVCAR3 cells. The 3328Luc-
OVCAR3 cells was treated with 10-7 M 1,25VD for 6 days and luciferase activity was 
determined. (D) ChIP assays. Soluble chromatin was prepared from OVCAR3 cells 
treated with ETOH or 10-7 M 1,25VD for 60 min. ChIP assays were performed with 
control (rat IgG) or anti-VDR antibody.  
0.0
0.5
1.0
1.5
2.0
2.5
0
2
4
6
8
10
12
ETOH       VD
ETOH   9-cis RA+ VD
A B
L
u
ci
fe
ra
se
A
ct
iv
ity
R
L
U
 x
 1
0-
6
L
u
ci
fe
ra
se
A
ct
iv
ity
R
L
U
 x
 1
0-
6
L
u
ci
fe
ra
se
A
ct
iv
it
y
R
L
U
 x
 1
0-
5
C
ETOH       VD
VDR       Rat IgG      Input
+ - + - + - VD
GADD45-VDRE-E
hTERT-VDRE
D
0.0
0.5
1.0
1.5
2.0
2.5
L
u
ci
fe
ra
se
A
ct
iv
ity
R
L
U
 x
 1
0-
6
L
u
ci
fe
ra
se
A
ct
iv
ity
R
L
U
 x
 1
0-
6
L
u
ci
fe
ra
se
A
ct
iv
it
y
R
L
U
 x
 1
0-
5
 72 
One putative DR3-type VDRE was identified in the hTERT promoter in a recent 
report (Ikeda, 2003). To determine if this putative VDRE is functional in 1,25VD-
mediated inhibition of telomerase activity in OCa cells, EMSAs were performed and the 
results showed that this VDRE bound recombinant VDR and RXR proteins (Fig. 18). The 
binding is specific for the VDR/RXR heterodimer since neither VDR nor RXR alone 
formed a detectable complex with the VDRE probes. The VDRE was displaced from the 
complexes with an excess amount of cold hOC VDRE but was not affected by the non-
specific sequence VDRE-C.  VDRE-C has been shown not to bind VDR/RXR in our 
previous study (Fig. 9B). 
           To determine whether binding the receptors to VDRE in vitro mediates the down-
regulation of hTERT by 1,25VD in OVCAR3 cells, a reporter gene with a 3.3 kb 
promoter region of hTERT containing the putative VDRE located upstream of the cDNA 
of firefly luciferase gene was analyzed. In OVCAR3 cells transiently transfected with this 
reporter, 1,25VD did not decrease the luciferase activity (Fig. 19A). This is consistent 
with the study in prostate cancer cells showing that this VDRE-mediated inhibition of 
telomerase activity required 1,25VD and 9-cis RA, not 1,25VD alone (Ikeda, 2003). 
However, in OVCAR3 cells the combination of 1,25VD and 9-cis RA did not decrease 
the activity of telomerase reporter (Fig.19B). There is also no detectable decrease in 
reporter activity by prolonging the treatment of 1,25VD to 6 days in OVCAR3 cells in 
which the reporter was stably integrated into the genome (Fig. 19C). 
   To find out if the putative VDRE interacts with VDR in vivo, ChIP assays were 
performed with anti-VDR antibodies. In the soluble chromatin prepared from  
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OVCAR3 cells treated with 1,25VD, the anti-VDR antibody precipitated the GADD45 
exonic region containing the functional VDRE (Fig.  12B), but could not precipitate 
hTERT promoter fragments containing the putative VDRE (Fig. 19D). These data 
indicate that VDR is not recruited to the putative VDRE in vivo.  It is concluded that in 
OVCAR3 cells the putative VDRE in hTERT promoter is not a functional VDRE. 
           3. The stability of hTERT mRNA is decreased by 1,25VD  
           The down-regulation of hTERT mRNA after 1,25VD treatment  could be due to the  
short half- life of the hTERT message. To  examine whether 1,25VD-mediated changes in 
hTERT mRNA stability contribute to its decreased expression, we performed Real- time 
PCR analysis using RNA from actinomycin D-treated cells. After OVCAR3 cells were 
treated for 3 days with 1,25VD or vehicle, transcription was inhibited by adding 
actinomycin D. At different time intervals, total RNA was isolated and hTERT mRNA 
was determined by Real-time PCR analysis. As shown in Figure 20 A, the level of 
hTERT mRNA, after normalization with GAPDH, decreased within approximately 10 hr 
in 1,25VD-treated cells, whereas hTERT mRNA from vehicle-treated cells was 
comparatively stable over this period of time.  The half- life of hTERT mRNA in 1,25VD 
treated and control cells is approcimately10 hr and 29 hr, respectively. The same results 
were obtained using a sencond probe and primers designed for another region of hTERT 
cDNA (Fig. 20B). The rate of degradation of the hTERT mRNA was increased by the 
addition of 1,25VD, which demonstrates that the decrease of hTERT mRNA by 1,25VD 
is due to its decreased stability.  
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Fig. 20. The stability of hTERT mRNA is decreased by 1,25VD. OVCAR3 cells were 
treated with 10-7 M 1,25VD (VD) or ETOH for 3 days, followed by treatment with 5 
mg/ml actinomycin D. Total RNA was extracted at 0, 2, 8, 12 hrs and subjected to 
 Real-time PCR using probe 1 (A) and probe 2 (B), as described in Meterials and 
Methods. 
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4. Telomerase stably-transfected cells have increased telomerase activity and 
prolonged telomere length. 
Ectopic expression of hTERT in telomerase-negative human fibroblasts and 
endothelial cells resulted in substantial telomerase activity and telomere maintenance. 
Furthermore, the ectopic expression of hTERT circumvented senescence and enabled 
these cells to be immortalized, i.e, proliferate indefinitely in culture (Hahn, 1999). To 
determine the role of telomerase in 1,25VD-induced growth inhibition in OVCAR3 cells, 
we tested whether the overexpression of telomerase was sufficient to abolish 1,25VD-
induced growth inhibition. hTERT cDNA, under the control of a viral promoter 
insensitive to 1,25VD, was stably transfected into OVCAR3 cells. As shown in Figure 
21A, the telomerase-OVCAR3 cell lines express 2-4 folds higher levels of telomerase 
activity than parental OVCAR3 cells.  Telomere length in OVCAR3 cells is ~3 kb as 
shown in Figure 21B. This is consistent with results from previous studies showing that 
telomere teminal restriction fragments (TRF) are ~3 kb in ovarian carcinoma cells (Villa, 
2000; Braunstein, 2001).  It has been known that the majority of human cancers have 
much shorter telomeres than the corresponding normal tissues; in many cases 
approaching that is associated with crisis in normal cells (2-4 kb) (Wynford-Thomas, 
1999; Liu, 1999). Telomerase plays an important role in maintaining stable telomere 
length. Telomere length in telomerase-OVCAR3 clones was prolonged to 6-10 kb, as 
shown  in Figure 21B.  The ectopic expression of hTERT in OVCAR3 cells dramatically 
increased telomerase activity and prolonged telomere length. 
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Fig. 21.  Telomerase-stably transfected cells have increased telomerase activity and 
prolonged telomere length. (A) Proteins were extracted from OVCAR3 cells and 
telomerase-OVCAR3 cells and subjected to PCR-TRAP assay, as described in Materials 
and Methods. (B) Genomic DNA extracted from OVCAR3 and Telomerase-OVCAR3  
were used to measure telomere length. Southern blot hybridization was performed as 
described in Materials and Methods. 
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Fig. 22.  Overexpression of telomerase blocks 1,25VD-induced down-regulation of 
telomerase activity.  (A) OVCAR3 cells and telomerase clones were treated with ETOH 
or 10-7 M 1,25VD for 6 days (6 d) or 9 days (9 d). The protein was extracted and 
subjected to PCR-TRAP assay, as described in Materials and Methods. (B) Genomic 
DNA extracted from OVCAR3 and Telomerase-OVCAR3 treated with 10-7 M 1,25VD 
(V) or ETOH (E) for 9 days to measure telomere length. Southern blot hybridization was 
performed, as described in Materials and Methods. 
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In contrast to parental cells, no dramatic decrease of telomerase activity or 
telomere length was observed in telomerase-OVCAR3 cells after treatment with 1,25VD 
for 6 or 9 days compared with vehicle treatment (Fig. 22 A and B). Cells with ectopic 
hTERT expression maintain high telomerase activity after 1,25VD treatment compared 
with parental OVCAR3 cells (Fig. 22A). These results demonstrate that ectopic 
expression of hTERT is sufficient to protect 1,25VD-inhibition of telomerase activity. 
Therefore, these cell lines can be used to determine whether telomerase plays any role 
with respect to 1,25VD.  
Although 1,25VD dramatically decreased telomerase activity, no remarkable loss 
of telomeric repeats was detected after 9 days of treatment with 1,25VD (Fig. 22B). No 
decrease in telomere length could be due to the fact that cells undergo only a few 
doublings in 9 days, the potential base pair loss in 9 days are estimated to be ~200 bp, the 
loss of telomeric repeats may not be measurable by conventional Southern Blotting. A 
recent study demonstrated that telomere dysfunction rather than the mean telomere length 
was modulated when glutathione (GSH) levels influenced the c-myc-dependent cell death 
(Biroccio, 2003). Telomerase and telomere structure are dynamically regulated in normal 
human cells and disruption of telomerse activity alters the maintenance of the 3’ single-
stranded telomeric overhang without changing the rate of overall telomere shortening 
(Masutomi, 2003), suggesting that modulating telomere integrity maybe essential 
regardless of telomere length. It is highly possible that although maintaining telomere 
length is important, 1,25VD down-regulated telomerase activity could regulate OCa cell 
growth through modulation of telomere integrity. 
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5. Overexpression of telomerase partially blocks 1,25VD-induced apoptosis 
and increases the ability to recover after 1,25VD withdrawal. 
To address the question if telomerase participates role in growth-suppressing 
activity of 1,25VD in OCa cells, we compared the response of telomerase-OVCAR3 
clones to 1,25VD to that of paretal OVCAR3 cells. The effect of 1,25VD on cell growth 
as well as the ability to recover from treatment after removal of the hormone was 
investigated. Similar to parental cells, growth of telomerase-OVCAR3 cells (Fig. 23) 
were also inhibited by 1,25VD,  but to a lesser extent. Cells overexpressing hTERT keep 
growing in the presence of 1,25VD while the growth of parental cells halted after 6 days 
treatment with 1,25VD. Telomerase clones are more resis tant to 1,25VD-induced growth 
inhibition. Additionally, after 9 days of 1,25VD treatment, the recovery of telomerase-
OVCAR3 cells was rapid compared to the recovery of the parental cell line (Fig. 24). Our 
observation suggests that ectopic expression of hTERT in OCa cells protects about 50% 
of 1,25VD reduced growth, although other mechanisms independent of telomerase may 
also exist. 
 Since overexpression of telomerase altered cell response to 1,25VD in the 
recovery assay, we next assessed whether alterations in apoptotic index occurred. 
Parental and telomerase-OVCAR3 cells were treated with 1,25VD and then analyzed by 
flow cytometry. As shown in Figure 25, in contrast to the massive apoptosis (70%) 
induced in parental cells after 9 days treatment with 1,25VD, telomerase clones showed 
fewer apoptotic cells (<40%). The ectopic expression of hTERT partially rescued long-
term 1,25VD  treated  OVCAR3  cells  from  cell  death. This may  contribute  to   
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Fig. 23.  Telomerase-OVCAR3 cells are less sensitive to growth inhibition by 
1,25VD. OVCAR3 and telomerase-OVCAR3 cells were plated in 96 wells and treated 
with 10-7 M 1,25VD (VD) or ETOH as a vehicle. Cell numbers were determined with the 
MTT assays. Eight samples were analyzed for each data point. *P<0.05 (versus ETOH 
treatment).  
0
2
4
6
8
10
ETOH
VD
0
2
4
6
8
10
ETOH
VD
0
2
4
6
8
10
12
ETOH
VD
OVCAR3
Telomerase
-OVCAR3#1
Telomerase
-OVCAR3#2
0         3       6       9    
Days of treatment
*
*
*
 81 
  
Fig. 24.  Telomerase-OVCAR3 cells recover quickly from 1,25VD treatment. 
OVCAR3 and Telomerase-OVCAR3 cells were pretreated with 10-7 M 1,25VD or ETOH 
for 9 days. Recovery of pretreated cells was assessed by plating pretreated cells in 96 
well plates. Cell numbers were determined with the MTT assay. Eight samples were 
analyzed for each data point. 
 
OVCAR3
Telomerase
-OVCAR3 #1
0
1
2
3
4
5
6
7
0
2
4
6
8
10
0
2
4
6
8
10
12
14
VD pretreatment
ETOH pretreatment
0      3      6     9    12  
Days of treatment
Telomerase
-OVCAR3 #2
 82 
 
 
Fig. 25.  Overexpression of telomerase partially blocks 1,25VD-induced apoptosis.
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Fig. 25.  Overexpression of telomerase partially blocks 1,25VD-induced apoptosis. 
 (A) OVCAR3 and Telomerase-OVCAR3 clones were treated with ETOH or 10-7 M 
1,25VD for 9 days. Apoptotic index was determined by flow cytometry and a 
representative profile is presented. (B) Bar graphs show percentage of apoptotic cells in 
two experiments. 
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 the reduced growth inhibition of telomerase clones by 1,25VD treatment (Fig. 23).  
Collectively, these studies show that in OVCAR3 cells down-regulation of 
telomerase is correlated to 1,25VD-induced growth inhibition and apoptosis. The 
enhancement of telomerase function in OVCAR3 cells, as measured by telomerase 
activity, allows the  cells to recover from 1,25VD treatment and rescues them from 
1,25VD-induced apoptosis. Telomerase activity remains a key parameter that determines 
long-term cell survival in OCa cells. This work supports our hypothesis that telomerase 
inhibition by 1,25VD may serve as an effective tool to eliminate OCa cells that have 
short telomeres.  
EB1089 is more potent than 1,25VD in suppressing OCa cell growth in vitro 
and in nude mice. 
The effective concentration of 1,25VD (10-7 M) is pharmacological, which is 
expected to induce hypercalcemia in vivo. EB1089, a 1,25VD analogue, is less calcemic 
and was shown to be more effective against breast (Colston, 1992), pancreatic (Colston, 
1997), colon (Akhter, 1996) and prostate (Blutt, 2000) cancers. To test whether EB1089 
can be used for long-term treatment and/or chemoprevention of OCa, our study 
investigated VDR expression in human ovarian tissues, the growth of OVCAR3 cells and 
tumor xenografts in nude mice.  
 In MTT assays, EB1089 is effective against OCa cells at concentrations 10 times 
lower than 1,25VD, making it a promising candidate for in vivo treatment of OCa (Fig. 
26 A and B).   As expected, EB1089  induced  GADD45  reporter  activity effectively 
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 Fig. 26.  EB1089 is more potent than 1,25VD in suppressing OCa cell growth. 
OVCAR3 cells were plated in 96 well plates and treated 1,25VD (VD) (A) or EB1089 
(EB) (B) at the indicated concentrations. Cell numbers were determined with MTT assay. 
Eight samples were analyzed for each data point, and the data were reproduced three 
times. 
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Fig. 27.  EB1089 is more effective than 1,25VD in inducing GADD45 reporter 
activity. OVCAR3 cells were transfected with 0.2 mg GADDLuc, 0.05 mg pCMVgal, 
0.05 mg p91023B-VDR and 0.05 mg pCMX-RXRb and treated with ETOH, 1,25VD or 
EB1089 at the indicated concentrations.  Luciferase activity was determined and 
normalized with cognate b-gal activity.  
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at concentrations 10 times lower than 1,25VD (Fig. 27), suggesting a mechanism of 
EB1089 action in OCa cells. 
To determine whether the effect of 1,25VD and EB1089 on OCa cell growth can 
be directly translated into tumor suppression in the whole animal, we tested the effect of 
EB1089 in OVCAR3 tumor xenografts. As shown in Figure 28A, EB1089 at 1mg/day/kg 
totally inhibited the growth of tumors while a dose of 0.3 mg/day/kg partially inhibited 
the growth. Based on statistical analysis of independent samples with the T-test, the 
difference between placebo control (6 tumors) and 1.0 mg/day/kg (9 tumors) is significant 
(p=0.003). The difference between the 0.3 (6 tumors) and 1.0 mg/kg/day group is also 
significant (p=0.04). The difference between placebo control and 0.3 mg/kg was not 
significant (p=0.281). This is probably due to the fact that the number of groups was 
small and the size of tumors was heterogeneous at the start of the study. In our 
experiments, each individual mouse was marked and the tumor volume was recorded 
separately; the difference between 0.3 mg/kg/day and placebo is obvious when the growth 
of each individual tumor was examined separately.  
 To determine if EB1089 is less calcemic, serum calcium levels were determined 
in treated nude mice (Fig. 28B). Blood tests at 30 days did not reveal significant increase 
in blood calcium. The levels in placebo (~9 mg/dl) and both of EB 1089 groups (9~10.5 
mg/dl) were within the normal range (7-11 mg/dl). As expected, 1,25VD treatment for 
1.0 mg/kg/day induced higher levels of serum calcium (11~12 mg/dl at day-15 and day-
30), which is outside the normal range. Importantly, no abnormality was seen in mice 
treated with EB1089 at 0.3 or 1.0 mg/kg/day for 4 weeks and normal body weight was 
maintained (data not shown).  
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Fig. 28.  EB1089 inhibits OCa xenograft growth.
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Fig. 28.  EB1089 inhibits OCa xenograft growth. (A) 2x106 OVCAR3 cells were 
injected s.c. into one site  in the dorsal side of nude mice. After the tumors grew to 150 
nm3, mice were randomly divided into three groups and treated with placebo or EB1089 
at indicated doses daily as described in Materials and Methods. The tomor size was 
measured every five days and the growth status of each tumor was recorded separately. *, 
p<0.01 compared with placebo group. (B) Average serum calcium levels for each 
treatment group. 
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VDR and RXR are expressed in precursors for epithelial OCa and normal 
ovarian surface epithelial cells are responsive to 1,25VD. 
If 1,25VD is useful for OCa prevention, its receptors should be expressed in OSE 
cells and benign ovarian tumors, the precursors for malignant epithelial OCa, which gives 
rise to more than 90% of human OCa. Indeed, our immunohistochemical studies showed 
that both VDR and RXR are expressed strongly in human OSE cells and in benign 
tumors. Skin tissues which express VDR and RXR were used as positive control and the 
primary antibody was substituted with IgG as negative control (Fig. 29).  
To test whether normal ovarian surface epithelial (OSE) cells respond to 
1,25VD’s growth suppression, primary human OSE cell cultures were treated with ETOH 
or 1,25VD and their growth was analyzed by the MTT assays. As shown in Figure 30, the 
growth of human OSE cells was suppressed by 1,25VD in a similar way as seen with 
OVCAR3 cells. These data clearly demonstrate that human primary ovarian cells are 
sensitive to 1,25VD. 
Collectively, the expression of VDR in human ovary and the growth inhibition of 
human primary OSE by 1,25VD indicate that 1,25VD analogue could also be used for 
chemoprevention. 
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Fig. 29.   Normal ovarian epithelial cells and benign adenomas express VDR and 
RXR. Paraffin sections of tissues were stained with anti-VDR (rat monoclonal 9A7) or  
anti-RXR (rabbit polyclonal) antibodies. The anti-RXR antibody was generated against 
RXRa, but also cross reacts with RXRb and RXRg. IgG controls were performed with 
normal ovarian sections (rat IgG for VDR and rabbit serum for RXR). 
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Fig. 30.   1,25VD suppresses human primary ovarian cell growth. Human primary 
ovarian epithelial cells were plated in 96-well plates and treated with 10-7 M 1,25VD 
(VD) or ETOH. Cell numbers were determined at the indicated times by the MTT assays. 
Eight samples were analyzed for each data point. * P<0.05 (versus ETOH treatment).  
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DISCUSSION  
 
To demonstrate the role of 1,25VD and it analogues in OCa treatment and 
prevention, the mechanism by which 1,25VD mediated its antiproliferative activity was 
explored using a VD sensitive OCa cell line (OVCAR3) as a model system. The effect of 
the 1,25VD analogue EB1089 on OCa cell growth was also investigated in vitro and in 
vivo. Cell cycle studies showed that 1,25VD increased the proportion of OVCAR3 cells 
in the G0/G1 and G2/M phase and decreased those in the S phase. 1,25VD also induced 
apoptosis in OVCAR3 cells.  
Furthermore, we have identified GADD45 and telomerase as target genes for 
1,25VD and suggest a model of VD action in OCa cells (Fig. 31). 1,25VD induces 
binding of the VDR/RXR heterodimer to the VDRE located in the fourth exon of 
GADD45 gene at a position downstream from the termination codon for protein 
translation. Presumably through the recruitment of co-activator complexes, the activated 
VDR/RXR interacts with the Pol II complex bound to the promoter and increases the rate 
of GADD45 transcription. This leads to an increase in the amount of GADD45 protein 
that, through a yet unknown undefined mechanism, decreases the level of cyclin B, the 
regulatory subunit of cdc2 kinase. The resulting decrease in cdc2 activity is then 
responsible for disturbed cell cycle progression to M phase. In addition, 1,25VD inhibits  
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Fig. 31.   Model for the integrated cellular pathways of 1,25VD action in OCa cells 
(See text for details). 
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telomerase activity by decreasing the stability of hTERT mRNA, not by the putative 
VDRE in the hTERT promoter which is not functional in vivo.  Importantly, hTERT 
clones are more resistant to 1,25VD-induced apoptosis and growth inhibition. In contrast 
to parental cells that recover slowly from prolonged treatment  with 1,25VD, hTERT 
clones re-grow quickly after 1,25VD withdrawal. Lastly, our investigation of the 
antiproliferative effects of EB1089 on OVCAR3 cells and xenografts without inducing 
hypercalcemia may indicate a novel preventive and therapeutic option fo r the treatment 
of OCa. 
Upregulation of GADD45 by 1,25VD is mediated through a novel exonic 
enhancer  
 Induction of GADD45 can be detected in cells within 2 hrs of treatment with 
1,25VD (Fig. 8B). With the lack of a VD effect on mRNA stability (Fig. 8C) and the 
identification of functional VDREs in the genome (Figs. 9-12), our data establish 
GADD45 as a primary and immediately early response gene for 1,25VD. Furthermore, 
our data suggest that GADD45 regulation is mediated through a VDR/RXR heterodimer, 
instead of a VDR/VDR homodimer. This conclusion is reached based on the inability of 
VDR to bind to all putative VDREs in EMSAs until the addition of RXR and the up-
shifting of the complexes by RXR antibody (Fig. 9). At variance with the belief that 
nuclear receptors forming heterodimers with RXRs bind DNA in the absence of ligand, 
our ChIP assays (Fig. 12B) clearly show that in vivo binding of VDR to the exonic 
VDRE is ligand-dependent. Recently, Yamamoto et al. (2003) reported a similar 
observation on VDRE located in the promoter of the OPN gene, suggesting that the 
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ligand dependency is common to VDREs located inside and outside the promoter 
regions. 
Since p53 in OVCAR3 cells is mutated (Yaginuma, 1992), the regulation of 
GADD45 transcription by 1,25VD obvious ly occurs independently of p53 activity. This 
is consistent with the identification of the VDRE in the fourth exon that is distant from 
the p53 binding site which is located in the third intron (Hollander, 1993). This is also 
consistent with the conclusion reached by a study of squamous cell carcinoma 
(Prudencio, 2001). Furthermore, the VD regulation of GADD45 is also likely to be 
independent of BRCA1 since the DNA element for this tumor suppressor is located in the 
promoter region (Jin, 2000). It is striking that four of the five putative VDREs bound 
VDR/RXR equally well in EMSAs, but only VDRE-E mediated the up-regulation of 
GADD45 reporter by 1,25VD. The other putative VDREs are either nonfunctional or 
may act in a negative way. Overall, the data suggest that the regulation of GADD45 by 
1,25VD is a complex process that may involve the interaction of the receptor bound to 
the VDRE and other transcription factors. The different VDREs may also function in a 
cell-specific manner to mediate the regulation of GADD45 expression by 1,25VD.  
GADD45 protein upregulation by 1,25VD is required for the hormone-
induced cell cycle arrest at the G2/M but not the G1/S checkpoint  
            Our studies link GADD45 induction specifically to the inhibition by 1,25VD of 
cell cycle progression through the G2/M checkpoint. This linkage was established using 
cells in which GADD45 expression was compromised by the anti-sense approach or 
genetic knock out. It is important to determine the effect of GADD45 anti-sense on 
1,25VD-induced growth inhibition in the stably transfected cells, which would reveal 
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whether G2/M arrest is a major or minor factor in the overall growth inhibition. However, 
our analysis with MTT assay revealed little difference in the overall response to 1,25VD 
between anti-sense GADD45 and control clones (data not shown). This may due to cell 
cycle arrest being shifted from G2/M to G1/S checkpoint in anti-sense clones.  
Previous studies (Akutsu, 2001) have shown that GADD45 induction in 
squamous cell carcinoma by 1,25VD is associated with an increased interaction with 
PCNA. Although we have not examined the association of GADD45 with PCNA, this 
seems unlikely in OVCAR3 cells. PCNA is required for DNA replication in S phase but 
our data show that G1/S arrest still occurs in OVCAR3 cells expressing the anti-sense 
cDNA of GADD45 (Fig. 13C and 13D). Instead of PCNA, our studies show a 1,25VD-
induced decrease in cdc2 activity, which is associated with a decrease in the level of 
cyclin B1 protein. The decrease was not observed in the stable clones expressing 
GADD45 anti-sense cDNA (Fig. 15). The data suggest that GADD45 mediates the effect 
of 1,25VD on cdc2 activity. Our data concur with the proposed role of GADD45 in G2/M 
arrest induced by certain types of DNA damaging agents (Wang, 1999; Zhan, 1999).  
Zhan et al. (1999) have shown that GADD45 inhibits the interaction between cyclin B 
and cdc2. Later, it was shown that GADD45-induced cell cycle arrest at G2/M is 
associated with an altered cellular distribution of cyclin B1 (Jin, 2002), which seems to 
require a functional p53. Our conclusions, however, differ from the above studies since 
we detected a decrease in the level of cyclin B1 protein (Fig. 15). As mentioned earlier, 
OVCAR3 cells contain a mutant p53 (Yaginuma, 1992). Obviously, GADD45 exerts its 
effect on cdc2 activity and the G2/M transition in the OCa cells independently of p53. It 
remains to be determined whether the effect of 1,25VD on G2/M in OCa cells is exerted 
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through GADD45 alone or in combination with another protein that functions similarly to 
p53.  
Besides its role in regulating G2/M transition, GADD45 plays an essential role in 
DNA repair and in the maintenance of genomic stability. MEFs derived from GADD45-
null mice exhibit aneuploidy, chromosomal abnormalities, gene amplification and 
centrosomal amplification (Hollander, 1999). GADD45-null mice display increased 
sensitivity to dimethylbenzanthracene-induced carcinogenesis (Hollander, 2001). It is 
intriguing that dimethylbenzanthracene increased female ovarian tumors more efficiently 
in GADD45-null mice than wild type (Hollander, 2001). GADD45 induction by 1,25VD 
through VDR suggests that VDR may act in a p53 independent tumor-suppressing 
pathway to affects ovarian genomic stability. Along this line, VDR has been shown to act 
as a bile acid sensor for the secondary bile acid lithocholic acid (LCA) (Makishima, 
2002), a potential enteric carcinogen that induces DNA strand breaks, forms DNA 
adducts and inhibits DNA repair enzymes. It will be interesting to show whether ovarian 
carcinogens or DNA-damaging processes (e.g. ovulation) activate VDR in ovarian 
epithelial cells and, if yes, whether the VD-independent VDR activation functions in 
DNA repair.  
Down-regulation of telomerase by 1,25VD is mediated through 
destabilization of hTERT mRNA 
Hormones regulate the expression of telomerase in hormone-responsive cell 
systems. In some cases, induction or repression of telomerase has been considered a 
consequence of maturation and/or growth arrest, rather than a direct hormonal effect. For 
example, androgens stimulate telomerase indirectly since the hTERT promoter construct 
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was not activated by androgen and transcription of the endogenous gene was not 
stimulated early enough in cultured cells to be considered a direct target of androgens.  
However, it has also been reported that inhibition of telomerase activity is an early event 
of the differentiation process in leukemia cells rather than its consequence (Albanell, 
1996; Savoysky, 1996). Retinoids and VD negatively regula te telomerase that is 
associated with differentiation in leukemia cells. However, it is not yet clear at which 
level of gene expression this down-regulation occurs. In addition, numerous studies 
showed that hormones directly regulate telomerase via different mechanisms. For 
example, estrogens activates telomerase through the direct interaction of ligand-activated 
ER with the ERE in the hTERT promoter. Progesterone regulates hTERT transcription 
via the MAP kinase cascade.   
There was a significant correlation of telomerase activity with hTERT mRNA 
expression but not with TP1 or hTR. hTERT is the major determinant of telomerase 
activity (Counter, 1998). In our study, the repression of telomerase activity by 1,25VD 
accompanied down-regulation of hTERT mRNA as shown by RT-PCR and confirmed by 
Real-time PCR.  
The present study demonstrates that 1,25VD down-regulates telomerase activity 
mediated through repression of hTERT mRNA (Fig. 17-20). The stability of hTERT 
mRNA was decreased by 1,25VD (Fig. 20), demonstrating that the regulation was 
posttranscriptional. Our findings provide direct evidence that hTERT is a target gene for 
1,25VD.  
Although EMSA revealed that the putative VDRE bound specifically to the 
VDR/RXR heterodimer, as shown by Ikeda et al, 2003, it is worth noting that in their 
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study, this VDRE only mediated the down-regulation of reporter activity by cotreatment 
of 1,25VD and 9-cis RA, but not 1,25VD alone. The limitation of this VDRE function 
may due to different cellular context. Transcriptional assays using luciferase reporter 
plasmids containing full length of hTERT promoter showed no down-regulation by 
1,25VD or by combination of 1,25VD and 9-cis RA in OCa cells.  Furthermore, ChIP 
analysis showed that no detectable binding of VDR to this VDRE in vivo. All these data 
indicate that this putative VDRE is not functional in OVCAR3 cells. Real-time PCR 
analysis revealed that 1,25VD decreased the stability of hTERT mRNA.  
Real-time PCR showed that hTERT mRNA was degraded to 50% within ~10 hr 
by treatment of 1,25VD, while no detectable increase in the number of apoptotic cells 
within this timeframe (data not shown). The time course of destabilization of hTERT 
mRNA by 1,25VD precedes induction of apoptosis by 1,25VD, suggesting that decreases 
in hTERT mRNA are not a result of the induction of apoptosis in these cells. 
To our knowledge, this is the first study incident showing that the stability of 
hTERT mRNA was regulated. This may open new aspects to study the regulation of 
hTERT, especially in the repression of telomerase.  
Sequence analysis of the hTERT promoter revealed binding sites for several 
transcription factors suggesting hTERT could be regulated by different factors in 
different cellular contexts (Cong, 2002). The oncogene c-myc has been shown to activate 
telomerase through two myc binding sites in hTERT promoter (Wu, 1999). Since 1,25VD 
have been shown to inhibit c-myc (Saunders, 1993) and c-myc binding sites are present in 
full- length hTERT reporter construct, this oncogene could mediate the repression of 
telomerase by 1,25VD. However, the persistent inhibition of hTERT mRNA in the 
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presence of cycloheximide and the lack of inhibition in reporter assays rule out the 
indirect effect of 1,25VD mediated through c-myc.  
Over-expression of hTERT allows the recovery of OCa cells after 1,25VD 
treatment and partially relieves 1,25VD-induced apoptosis 
Treatment of 1,25VD in parental OCa cells causes massive apoptosis leading to 
the loss of the entire population. In addition to the decrease of telomerase activity, 
apoptosis was also induced by 1,25VD and the recovery from 1,25VD treatment was 
slow in parental OVCAR3 cells. By contrast, the hTERT-overexpressing cells maintained 
telomerase activity at higher levels and telomere length at a size much longer than 
parental cells over time, 1,25VD-induced apoptosis and growth inhibition were partially 
rescued, leading to cell recovery and growth (Fig 21-25). This indicates that a certain 
level of telomerase activity may play an important role in protecting cells from apoptosis 
in OCa cells. Our results provide the first direct evidence that telomerase may affect 
1,25VD-induced apoptosis in OCa cells.  
It is well known that there is strong correlation between telomere function and 
senescence (Kolquist, 1998). Telomerase activation is shown as one of the three steps 
needed to overcome senescence and transform normal human epithelial cells to cancer 
cells (Hahn, 1999).  Cells undergoing senescence have a large and flat morphology, 
express acidic beta-galactosidase (b-gal) and show a permanent G0/G1 arrest, whereas 
apoptotic cells show evidence of DNA fragmentation (Biroccio, 2003). Many studies 
have linked telomerase inhibition to apoptosis. For example, hTERT-expressing cells 
were more resistant to apoptosis induced by UV and g- irradiation (Gorbunova, 2002). 
Following ectopic expression of dominant-negative TERT into transformed cells, growth 
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inhibition and apoptosis was induced (Hahn, 1999; Zhang, 1999).  In our model system, 
1,25VD-induced decrease in telomerase activity is correlated with 1,25VD-induced 
apoptosis, not senescence. This is supported by our data that the senescence b-gal, a 
marker for senescence, was not induced by 1,25VD treatment in OCa cells (data not 
shown). Instead, extensive cell death was observed. Our data strongly suggested that 
telomerase plays a critical role in cellular resistance to apoptosis.  
Little is known about the signaling pathways mediating VD-induced apoptosis. 
Several factors involving mitochondrial and caspase changes were investigated.  Bcl-2 is 
down-regulated in VD-induced apoptosis in breast and prostate cancer cells (Mathiasen, 
1999; Blutt, 2000), pro-apoptotic Bak is induced in colon cancer cells (Diaz, 2000). VD 
induced–apoptosis is caspase-dependent in prostate cancer cells, while in breast cancer 
cells, calpain may replace caspases as a key mediator (Mathiasen, 1999 and 2002).  
It is assumed that some anti-apoptotic pathways are activated by telomerase or 
that the apoptotic pathway induced by 1,25VD is blocked by telomerase overexpression. 
As suggested in a recent report, overexpression of wild-type hTERT in HeLa cells 
increases their resistance to apoptosis, induced by the DNA damaging agent etoposide, 
and TERT suppresses apoptosis at a premitochondrial step by a mechanism requiring 
reverse transcriptase activity and 14-3-3 protein-binding (Zhang, 2003). Overexpression 
of Bcl-2 and the caspase inhibitor zVAD-fmk  protected cells against apoptosis in the 
presence of telomerase inhibitors in pheochromocytoma cells (Fu, 1999). All these data 
suggest that the telomerase function is upstream of caspase activation and mitochondrial 
dysfunction. But different from those DNA damaging reagents- induced apoptosis, 
1,25VD induced apoptosis could mediate through different pathway. It will be 
 103 
worthwhile to study how telomerase inserts anti-apoptotic function to block 1,25VD-
induced apoptosis. 
Transformed human cells enter crisis once TRF reach a length of ~4 kb. 
Telomeres that have been shortened to this degree may no longer protect chromosome 
ends, and in turn, may lead to the genomic instability and cell death (Counter, 1998). This 
is consisted with the fact that many cancers have mean telomere lengths well below 
normal and often close to the threshold required for cell survival.  Tumor cells, such as 
OVCAR3 cells, have very short telomere and appear to require telomerase activity even 
for short-term viability. In OVCAR3 cells, the short telomere length of  3 kb is close to 
the threshold level and was maintained by high telomerase activity.   It is postulated that 
in these cells telomerase activity is required at nearly every division of cells replicating 
with critically short telomeres and inhibition of telomerase activity in these cells causes 
loss of viability through activation of apoptotic pathways (Zhang, 1999).  
It is known that telomerase inhibition may lead to a phenotypic lag in which cells 
would continue to divide until the point at which the telomeres became critically short. 
This lag phase varies depending on the initial telomere length. In terms of telomerase as 
anti-cancer target for VD, OCa cells, which have short telomeres, could have short lag 
phase and thus be efficiently inhibited by VD.  
1,25VD analogue  EB1089 has potent anti-tumor activity in vitro and in vivo, 
and has strong implications to cancer treatment and prevention 
Since the pharmacological levels of 1,25VD (10-7 M) induce hypercalcemia, the 
goal of our research is to establish synthetic 1,25VD analogues, such as less calcemic 
EB1089, as chemotherapeutic treatment for OCa.  
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Our study is the first to demonstrate EB1089 inhibits growth of OCa cells and 
tumor xenografts in nude mice. Importantly, the tumor inhibition in vivo occurred without 
physical symptoms of hypercalcemia, and particularly promising is the minimal effect on 
serum calcium (Fig. 28). It demonstrates that EB1089 may be suitable for long-term 
treatment and/or chemoprevention.  
EB1089 could also be useful for treating VD-resistant cancers. A recent study 
demonstrated that down-regulation of 24-hydroxylase enhaced 1,25VD levels and 
improved mitotic control of tumor cells (Cross, 2003). The rapid breakdown of 1,25VD 
was suspected to be the cause of the resistance of DU145, a prostate cancer cell line, to 
1,25VD. In the presence of the 24-hydroxylase inhibitor, growth of DU145 cells was 
inhibited by 1,25VD and as much as in LNCaP cells (Zhao, 2001). EB1089 has 50-fold 
lower affinity than 1,25VD for 24-hydroxylase, and it is more slowly inactiviated by 24-
hydroxylasion (Roy, 1995), supporting the potential effect of EB1089 in the treatment of 
VD-resistant cancers. 
The pathogenesis of epithelial OCa is not completely understood, but it is 
believed that the process of recurrent ovulation (incessant ovulation) causes genetic 
damage to ovarian epithelial cells and that sufficient genetic damage can lead to OCa in 
susceptible individuals (Rodriguez, 2003). According to this model, reproductive and 
hormonal factors, including VD, retinoids, and non-steroidal anti- inflammatory drugs,  
may decrease OCa risk via their inhibitory effects on ovulation, leading to the biologic 
effects on the ovarian epithelium that are cancer preventive. Along this line, VDR 
expression is required for 1,25VD-mediated growth effects. We have shown the 
expression of VDR and its heterodimer partner, RXR, in human ovary and the response 
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of primary human ovarian cells to 1,25VD. These data indicate that the human ovary is a 
VD responsive organ and can be impacted strongly by “environmental” VD, leading to 
decreased OCa risk.  
Most tumors have compromised p53 function and half of OCa are estimated to 
have lost p53 function, thus becoming refractory to drugs targeting p53 pathways. 
Examination of p53- independent response in p53-mutant OVCAR3 cells warrants closer 
attention. These tumors may however still be sensitive to synthetic VD since 1,25VD 
induces GADD45 and inhibit telomerase in a p53- independent manner. Better 
understanding of the molecular mechanism of VD is critical for determining the ultimate 
utility of 1,25VD analogues in the clinic. 
In conclusion, molecular studies show that 1,25VD inhibits OCa cell growth and 
is mediated through regulation of specific genes including GADD45 and telomerase.  Our 
preclinical data show that 1,25VD analogue reduces OCa development in animals. Data 
from normal human ovarian tissues and cells demonstrate the presence of VDR and a 
response to 1,25VD. Studies from cellular, molecular and animal levels strongly suggest 
that VD represents a molecular target for chemotherapy and chemoprevention of OCa.
 106 
 
           
 
SUMMARY AND THE PERSPECTIVES OF FUTURE STUDY 
 
 OCa is a deadly disease and its etiology is largely unknown. Lack of both reliable 
detection methods and early symptoms results in poor prognosis for patients with OCa. 
Relapse and resistance to current treatment necessitate the development of new 
therapeutic methods to fight this deadly disease.  Our studies on VD action in OCa 
suggest that 1,25VD and its synthetic analogues may be effective therapeutic treatments 
for OCa.  
GADD45 is identified as one of the primary target genes by 1,25VD in OCa cells. 
Based on the similarity to concensus sequences, several putative VDREs identified by 
EMSA are localized in GADD45 introns or exons but not in the promoter region. 
Receptor response elements usually lie in the promoter region of regulated gene and all 
known VDRE have been identified in the promoter. Of particular interest to our study is 
VDRE in the 3’ untranslated region of exon 4 plays critical role in mediating the 
transcriptional regulation of GADD45. To our knowledge, this is the first study showing 
that a vitamin D enhancer element is localized in the exon region. Our study can not 
exclude that other VDREs act in a negative way and that different VDREs in the 
GADD45 genome may function in a cell-specific manner to mediate the regulation of 
GADD45 expression by 1,25VD.  
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Since the specific VDRE is located in an exon and falls into the 3’ untranslated 
region og GADD45, it provides an excellent model system to study how DNA response 
elements in the 3’ end of the coding sequence may regulate the transcription of a target 
gene via the Pol II complex which bound to the promoter at the 5’ end. Site-specific 
transcription factors (Agalioti, 2002), including nuclear hormone receptors (Louie, 2003), 
recruit components of the Pol II complex to the enhancer sequences and, after co-
activator mediated chromatin remodeling, the adjacent nucleosome slides downstream to 
initiate transcription. It remains to be seen whether DNA response elements at the 3’ end 
of the coding sequence recruit Pol II components and, if so, how the modified 
nucleosome moves to the correct position to permit initiation of transcription since the 
nucleosome has to either slide upstream by a significant distance or jump across the 
coding region to initiate transcription.  
VD-dependent apoptosis and cell cycle arrest could engage activation of the p38 
MAPK pathway and induction of GADD45 (Sutter, 2003). Recent data showed that 
GADD45 is reqired for p38 activation. Disruption of GADD45 abrogates H-ras induced 
cell-cycle arrest and p38 activation (Bulavin, 2003). It is quite likely that upregulation of 
GADD45 by 1,25VD is required for activation of p38, that may mediate 1,25VD-induced 
growth inhibition. In support this hypothesis, it is known that most biological actions of 
VD are mediated through the nuclear VDR-mediated expression of target genes.  The 
study of VDRKO mice showed that nongenomic effects of VD in osteoblasts are 
abrogated in the absence of nuclear VDR (Erben, 2002) and suggest that some 
nongenomic responses require a functional nuclear VDR. Using GADD45 as a model 
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system, future work may decipher the cooperation of nongenomic and genomic effects of 
VD. 
 Given that telomerase activity is regulated at multiple levels by different stimuli, 
including hormones, the mechanisms involved in telomerase regulation are far from 
established. Our data addressed a novel mechanism of down-regulation of telomerase by 
1,25VD. Better understanding of the regulation of telomerase by 1,25VD will provide the 
basis for telomerase activity in VD-targeted therapy. 
Although hTERT is regulated tightly at the promoter machinery and a putative 
VDRE in the hTERT promoter responds to a combination of 1,25VD and 9-cis RA in 
certain prostate cancer cells, it fails to respond to 1,25VD alone (Ikeda, 2003). It is not 
unusual that sequences match in vitro but do not provide a functional VDRE (Colnot, 
2000; Gonzalez, 2002). We provide strong evidence that VD increase the degradation of 
hTERT mRNA by real-time PCR analysis using 2 probes. Our study is the first to 
demonstrate down-regulation of telomerase mediated by decreasing the hTERT mRNA 
stability.  
Given that upregulation of hTERT mRNA and telomerase activity induced by 
multiple oncogenetic factors in cancer cells, degradation of hTERT mRNA by 1,25VD 
could be an effective way to suppress the effect of multiple oncogenic pathways in OCa. 
Recent studies showed that double-stranded RNA, including small interfering 
RNA (siRNA) and microRNA (miRNA) can induce the degradation of homologous 
RNAs in organisms as diverse as protozoa, animals, plants and fungi, resulting in 
posttranscriptional gene silencing (Lewis, 2003). MiRNA are endogenous ~22nt RNAs 
that arise from larger precursors transcribed from non-protein-coding genes. SiRNA arise 
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by cleavage of long, double-stranded RNAs. Despite the differences in origin, miRNA 
ans siRNA are functionally interchangeable (Carrington, 2003; Nelson, 2003). 1,25VD 
induced degradation of hTERT mRNA may provide a model to study the 
posttranscriptional repression of hTERT mRNA by double-stranded RNA. hTERT is not 
included in those ~400 targets of mammalian miRNA identified in the present database, 
perhaps due to the limited sensitivity of current bioinformatic methods. The actual 
number of target genes regulated by each miRNA is likely to be substantially higher 
(Lewis, 2003). It remains to be seen if hTERT would be a target for miRNA; if so, it will 
be important to establish how 1,25VD mediates down-regulation of hTERT mRNA 
through MiRNA.   
The ability of 1,25VD to induce cell cycle arrest and apoptosis without the 
involvement of p53 may prove useful in therapy. It is known that p53 stimulates the 
activities of p21/WAF1, gadd45 and bax genes to enhance their expression as a 
transcriptional factor resulting in cell cycle arrest, DNA repair and apoptosis (Bargonetti, 
2002). p53 is mutated in 50% of human malignancies, including ovarian cancer and 
tumors with mutant p53 resist conventional p53-target therapy. In our nodel system, 
1,25VD stimulates GADD45 and down-regulates telomerase in a p53- independent 
manner. 1,25VD therapy might compensate or substitute for part of the p53 function to 
induce cell cycle arrest and apoptosis. 1,25VD may prove valuable candidates for treating 
OCa, especially those OCa that have acquired resistance to other apoptosis- inducing 
agents due to a mutation in p53. 
VD decreases the generation of single-strand DNA induced by diethylnitrosamine 
(DEN), a mutagen that induces chromosome aberrations (Basak, 2000). DNA double 
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strand breaks are generated from mutagen- induced DNA lesions in the S-phase of the cell 
cycle. It is reasonable to assume that double strand breaks are repaired in the G2 phase by 
post-replicational repair mechanism. Therfore, VD-mediated suppression of double 
strand breaks could be mediated through GADD45, which has been shown to play role in 
DNA repair. GADD45 modified DNA accessibility on damaged chromatin (Carrier, 
1999) and affects chromatin remodeling of templates concurrent with DNA repair. 
Slower nucleotide excision repair was found in GADD45 deficient keratinocytes exposed 
to UV (Maeda, 2002). Based on these data GADD45 may participate in the coupling 
between chromatin assembly and DNA repair.  Since telomerase maintains the telomere 
length and contributes to chromosome stability (Cech, 2004), it will be worthwhile to 
investigate the role of GADD45 and telomerase in VD-protected chromosome stability 
and induced DNA repair. These two pathways will provide useful targets for DNA-
damaging chemotherapeutics against p53-defective OCa, which have decreased ability to 
repair chemotherapeutic damage.  
We were first to provide preclinical data on the 1,25VD analogue EB1089 in 
OCa. The goal of future studies is to test EB1089 or other promising 1,25VD analogues 
in clinical trial of OCa. To increase the antiproliferative potency without increasing side 
effects, use of less calcemic analogues appears to be the most reasonable approach. 
Several promising new synthetic VD analogs are also under development, such as KH-
1060, LG190119, deltanoids, 1-alpha-hydroxyvitamin D5, vitamin D2, QW-1624F2-2, 
etc.   
EB1089 has been widely used in breast and colon cancer patients and stabilization 
of disease was observed in a phase I trial (Gulliford, 1998). In a phase II study of EB1089 
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in patients with inoperable hepatocellular carcinoma, strikingly, out of 33 patients, two 
had complete response, 12 stable diseases. Complete regression appeared after 6 and 24 
months of treatment and lasted 29 to 36 months (Dalhoff, 2003). EB1089 was also well 
tolerated. Most patients tolerated a daily dose of 10 mg of EB1089. A Phase III trial in 
hepatoma are currently ongoing. These studies showed EB1089 response by a reduction 
of solid tumor size and provide the rationale that EB1089 can be used for treatment. The 
effectiveness of 1,25VD analogues in slowing the progression of prostate cancer, was 
shown in a study of an oral 1,25VD analogue (Rocaltrol) to treat early recurrent prostate 
cancer. PSA doubling time was significantly prolonged by the treatment in all 7 cases 
(Zhao, 2001).  
Administration of 1,25VD analogues through dietary supplementation suggests 
that oral ingestion of VD-based chemotherapy is an effective and feasible approach.  Oral 
administration and long-term safety of 1,25VD analogues clearly has the advantage in 
terms of feasibility of cancer chemotherapy and chemopreventive agents (Welsh, 2003).  
Our study showed human OSE growth was inhibited by 1,25VD and that VDR, 
RXR are expressed in normal human ovary tissues, which support the suspected role of 
VD in OCa initiation. Our data suggest that VD may have a cancer preventative effect. 
While numerous issues remain to be addressed, it is essential to investiga te the anti-tumor 
activity in the OCa “prevention” model after defining the downstream targets of VDR in 
the normal ovary.  
In summary, we link the specific molecular pathway to 1,25VD’s biological 
function in this study. We provide the first molecular evidence that G2/M arrest by 
1,25VD in OCa cells is mediated through the induction of GADD45 via a novel exonic 
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enhancer. We are also first to show that 1,25VD induced-apoptosis is mediated by 
destabilization of hTERT mRNA and a decrease in telomerase activity.  In addition, our 
study is the first to demonstrate that 1,25VD analogue EB1089 inhibits OCa xenograft in 
vivo. With the ubiquitous expression of VDR and RXR in ovarian tissues and response of 
primary OSE to 1,25VD, our data strongly suggest further investigation of less calcemic 
synthetic 1,25VD analogues as chemopreventive and chemtherapeutic agents against 
OCa.  Furthermore, half of OCa is estimated to lose p53 function, thus becoming 
refractory to drugs targeting p53 pathways. These tumors may however still be sensitive 
to synthetic VD since 1,25VD induces GADD45 and inhibits telomerase in a p53-
independent manner. 
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MATERIALS AND METHODS 
 
 
Materials 
pHG45-HC containing the 8 kb genomic sequence of human GADD45  
(Hollander, 1993),  pCMV45 containing the open reading frame of human GADD45 
cDNA and pCMVAS45 containing human GADD45 cDNA in the anti-sense orientation 
(Zhan, 1994), pCMVgal (Li, 2003), p91023B-VDR (Baker, 1988; Hilliard, 1994), 
pCMX-RXRb  (Mangelsdorf, 1992), p23 containing rat 24-hydroxylase promoter in 
pMAMMneoLuc (Arbour, 1998) and pBabhTERT (Vaziri, 1998) hTERT reporter 
construct pGL3-3328Luc (Kyo, 1999)have been described previously. pGL3-promoter, 
pGL3-basic and pGL3-control vectors were from Promega (Madison, WI). MEFs from 
wild type and GADD45-null mice have been described (Hollander, 1999). 1,25VD was 
from Calbiochem (La Jolla, CA).  EB1089 was kindly provided by Dr. Binderup of Leo 
Pharmaceuticals Products (Ballerup, Denmark). Baculovirus-expressed human VDR 
protein, human RXRb  protein and anti-RXRb  antibody were from Affinity BioReagents 
Inc. (Golden, CO). Anti-VDR antibody was from Chemicon International (Temecula, 
CA). Anti-Flag M2 antibody and anti-b-actin antibody were from Sigma (St. Louis, MO). 
Anti-GADD45 antibody (C-20), ant i-cdc2 antibody and anti-cyclin B1 antibody (D11) 
were from Santa Cruz Biotech (Santa Cruz, CA). All oligonucleotides were synthesized 
by Invitrogen (Carlsbad, CA). The sequence of primers used for the construction of 
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GADDLuc reporter by polymerase chain reaction (PCR) is: 5’-
GGTGGTACGCGTCCCGAACTTCTCTTACCTACC-3’ (forward) and 5’-
GGTGGTAGATCTACCCAAACTATGGCTGCACAC-3’ (reverse). The sequence of 
the oligonucleotides in sense orientation for producing complementary double strand 
oligoes for EMSA and site-mutagenesis is listed below: human OC VDRE 5’ –
ttggtgactcaccGGGTGAacgGGGGCAtt- 3’; putative GADD45 VDRE-A 5’ –
ttgggcgtgcagGGGTCAtggGGGGTGacg- 3’; putative GADD45 VDRE-B 5’ –
taggtggGGGTCAggaGGGTGGctgcctttgt- 3’; putative GADD45 VDRE-C 5’ –
aactGTTTCActcAGGTCAgggtaacaagt- 3’; putative GADD45 VDRE-D 5’ –
cagcttgGGTTGCatgGGTTCAgactttgc- 3’; putative GADD45 VDRE-E 5’ –
gccaaggGGCTGAgtgAGTTCAactacatg- 3’; putative hTERT VDRE 5’ –
cacccactggtaaggAGTTCAtggAGTTCAat- 3’; primer for the mutation of VDRE-A 5’ –
gtgcagGGGTCAtggGGGtTtacggggccgcggga- 3’; primer for the mutation of VDRE-B 5’ 
–GGGTCAggaGGGTttctgcctttgtccgactagagtg- 3’; primer for the mutation of VDRE-D 5’ 
–cagcttgGGTTGCatgGGTTttgactttgcaatgtgtag- 3’; primer for the mutation of VDRE-E 
5’ –gccaaggGGCTGAgtgAGTTttactacatgttctggg- 3’. Capital letters are used to indicate 
the hexameric core binding motifs in the VDRE primers and bold letters in lowercase are 
used to indicate the nucleotides in the mutagenesis primers that are different from the 
wild type sequence. The sequence of primers for chromatin immunoprecipitation (ChIP) 
assays is listed below: VDRE-E region (2565/2767) -CTGAACGGTGATGGCATCTG- 
3’ (forward) and 5’ -CTGTTTCAACACAGCTTCCTTC- 3’ (reverse); promoter region-1 
(-1492/-1241) 5’-GTTGTCCATGGCTGACAACA-3’ (forward) and 5’-
GCTCCCACATGCTTGCATTC-3’ (reverse); promoter region-2 (-505/-310) 5’-
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CACTTCTGAGGTAAACTTTGC-3’ (forward) and 5’-
GAAGCAGGCTGCCAAGTGTT-3’ (reverse). 
Colorimetric methylthiazole tetrazolium (MTT) assays and statistical analysis  
To measure cell growth, OVCAR3 cells were plated at 2 × 103 cells/well in 96-
well plates and treated with VD or vehicle. MTT assays were performed as described (Li, 
2001). OD595 was read on a MRX microplate reader (DYNEX Technologies, Chantilly, 
VA). 
For cell growth and cell cycle analyses, statistical analysis was performed using 
the independent-samples t test. P< 0.05 was considered to be statistically significant. 
Cell cycle and apoptosis analysis by flow cytometry 
To determine the cell cycle distribution, cells were harvested by trypsin digestion 
and fixed with 70% ethanol in PBS for 12 hours at 4 oC. Fixed cells were incubated 
overnight with 100 mg/ml RNase, stained with 50 mg/ml propidium iodide at 4 oC and 
subjected to cell cycle analysis on a FACScan (Becton Dickinson, Mountain View, CA). 
To determine the apoptosis, cells were harvested by trypsin digestion and washed with 
PBS. Cell suspension in 1x assay buffer was added annexin V-FITC and propidium 
iodide and incubated for 15min, then subjected to flow cytometry. 
Northern blot analysis 
To determine the level of GADD45 mRNA, Northern blot was performed as 
described (Zhang, 2003). Briefly, OVCAR3 cells were incubated with 1,25VD or vehicle 
for the indicated times. Total cellular RNA was isolated by TRIzol (Invitrogen) method 
following manufacture’s instruction. Samples containing 20 mg RNA were run on a 1% 
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agarose gel in denaturing gel buffer (Ambion, Austin, TX) and transferred onto a nylon 
membrane. The membrane was pre-hybridized at 65 oC for 4 h and hybridized with the 
GADD45 or GAPDH probe at 65 oC for overnight. Washes were performed in high 
stringency buffers. To prepare GADD45 probe, full- length GADD45 cDNA was released 
from pCMV45 vector with HindIII/XbaI digestion, separated and recovered from agarose 
gel. GAPDH probe was from Ambion. The probes were labeled with 32P using random-
primed DNA labeling kit (Ambion). Signal densities were analyzed with scion Image 
software (Scion Corp., Frederick, MD). 
Gel mobility shift assay (EMSA) 
 EMSA was performed as described (Li, 2003; Gonzalez, 2002) with 
modifications. Briefly, double-stranded oligonucleotides were end-labeled with 32P using 
a T4 polynucleotide kinase labeling system (Life Technologies, Rockville, MD).  1 ml of 
radiolabeled probe (roughly 50,000 cpm) was mixed with 19 ml DNA binding reaction 
mixture that contains 250 ng VDR, 250 ng RXR, 10 mM Tris-Cl (pH7.9), 100 mM KCl, 
0.1 mM EDTA, 15% glycerol, 100 mg/ml poly(dI:dC), 0.1 mg/ml bovine serum albumin, 1 
mM DTT and 10-7 M 1,25VD. The mixture was incubated at room temperature for 30 
minutes. For competition experiments, VDR/RXR was pre- incubated with 2 mg anti-
RXRb , anti-Flag M2 antibody or excess amount of cold probes on ice for 20 minutes 
before the EMSA reaction. The reaction mixture was resolved in a 5% non-denaturing 
polyarylamide gel and protein-oligo complexes were revealed by autoradiography. 
Construction of luciferase reporter plasmids, deletion and site-directed 
mutagenesis 
 117 
To construct GADDLuc, GADD45 genomic DNA fragment from +366 to +2926 
was amplified by PCR using primers described in the Material.  The forward primer 
contains a MluI and the reverse primer a BglII site. The amplified PCR fragment was 
cloned into the MluI and BglII sites of pGL3-promoter vector.  
Luc1 was generated by digesting the GADDLuc with KpnI and religation. Luc2 
was generated by digesting GADDLuc with MluI and EcoRI, filling with Klenow 
fragments and religation. Luc3 was generated by sub-cloning into BglII site of pGL3-
promoter vector a 440 bp DNA fragment released from GADDLuc with BamHI and 
BglII. Luc4 was generated by digesting GADDLuc with BglII and EcoRI, filling with 
Klenow fragments and religation.   Luc5 was generated by sub-cloning into pGL3-
promoter vector at KpnI and BglII sites a 777 bp fragment released from Luc2 with KpnI 
and BamHI. 
Site-directed mutagenesis was performed as described (Lee, 2002) using 
QuikChange Site-directed Mutagenesis kit (Stratagene, La Jolla, CA). The sequence of 
all mutant constructs was verified by DNA sequencing.   
Transcriptional analysis 
For transfection studies, OVCAR3 cells were plated in 15% FBS RPMI 1640 
medium at 1 ´ 105 cells/well and HeLa cells in 10% FBS DMEM at 5 ´ 104 cells/well in 
12-well plates. On the next day, OVCAR3 cells were transfected by Lipofectamine Plus 
and HeLa cells by Lipofectamine following the protocol from Invitrogen.  4 h post-
transfection, cells were treated with 1,25VD or vehicle in fresh medium for 36 h.  Cells 
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were harvested and luciferase and b-galactosidase (b-gal) assays were performed as 
described (Lee, 2000 and 2002).   
Chromatin immunoprecipitation (ChIP) assays  
For ChIP assays, OVCAR3 cells were treated with EOH or 10-7 M VD for 60 min 
and cross- linked with 1% formaldehyde at room temperature for 10 min. Then, the cells 
were incubated with 0.125 M glycine for 5 min, washed, scraped in ice-cold PBS 
containing protease inhibitor cocktail (Roche) and lysed in buffer (pH 8.0) containing 5 
mM PIPES, 85 mM KCl, 0.5 % NP 40 and protease inhibitor cocktail. Cell nuclei were 
re-suspended in lysis buffer containing 50 mM Tris-Cl (pH. 8.1), 10 mM EDTA, 1% SDS 
and protease inhibitor cocktail. Soluble chromatin was prepared by sonication and diluted 
in buffer containing 16.7 mM Tris-Cl (pH 8.1), 0.01 % SDS, 1.1% Triton X 100, 1.2 mM 
EDTA, 167 mM NaCl and protease inhibitor cocktail. The diluted chromatin solution was 
pre-cleared with pre- immune serum and protein G agarose (Santa Cruz) pre-coated with 
sheared sperm DNA (Ambion). Immunoprecipitations were carried for overnight at 4 oC 
with rat anti-VDR antibody or Rat IgG (Sigma) followed by incubation with pre-coated 
protein G agarose for 2 h at 4 oC. The beads were sequentially washed at room 
temperature for two times (10 min/wash) in each of the following buffers: the dilution 
buffer, TSE-500 wash buffer containing 20 mM Tris-Cl (pH 8.1), 0.1% SDS, 1% Triton 
X 100, 2 mM EDTA, 500 mM NaCl) and LiCl/detergent wash buffer containing 100 mM 
Tris-Cl (pH 8.1), 1% NP40, 1% deoxycholic acid, 500 mM LiCl). After the final wash in 
TE buffer containing 10 mM Tris-Cl (pH 8.0) and 1 mM EDTA, the immunocomplexes 
were eluted from the beads with 50 mM NaHCO3 and 1% SDS for two times. The 
immunocomplexes were pooled and heated at 65 oC overnight to reverse the cross-
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linking. DNA was extracted from the immunocomplexes using a QIAquick Spin Kit 
(Qiagen, CA). 2 ml out of 30 ml DNA extract was used for PCR.  
Immunoblotting analysis 
Immunoblotting analysis of GADD45 protein was performed as previously 
described (Li, 2001) with modification. Briefly, cells were harvested in lysis buffer 
containing 50 mM Tris-Cl (pH 7.5), 1% NP-40, 0.25% deoxycholic acid, 400 mM NaCl, 
1 mM EDTA, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 1 mM NaF, and 
protease inhibitor cocktail. The protein concentration of the cell lysate was assayed using 
Bio-Rad kit. Extracts containing 50 mg of protein were separated on a sodium dodecyl 
sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) and transferred to 
nitrocellulose membrane.   GADD45 was detected using ECL Kit following the 
manufacture’s instruction (Amersham-Pharmacia Biotech, Piscataway, NJ). The 
immunoblotting analysis of cdc2, cyclinB1 and VDR was performed similarly as for 
GADD45 except that the cell extracts were prepared in buffer containing 20 mM Tris-Cl 
(pH 7.5), 300 mM NaCl, 3 mM EDTA, 3 mM EGTA, 100 mM Na3VO4, 1% NP-40, and 
protease inhibitor cocktail (Zhang, 2003). 
Establishment of stable clones from OVCAR3 cells 
OVCAR3 cells were transfected with 10 mg pCMVAS45 or hTERT plasmid 
together with 0.5 mg pcDNA3 for the establishment of GADD45 anti-sense, telomerase 
stable clones. pcDNA3 alone transfected into OVCAR3 cells for the Vector-OVCAR3 
controls. For the establishment of stable clones with GADDLuc reporter, OVCAR3 cells 
were transfected with 10 mg GADDLuc plasmid and 0.5 mg pcDNA3. All stable clones 
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were obtained through selection with 100 mg/ml G418 for a period of about 4 weeks and 
isolated by cloning with glass cylinders.  
In vitro immunocomplex kinase assays   
In vitro immunocomplex kinase assays were performed as described (Lee, 2000) 
with minor modifications. In brief, cells were washed with ice-cold PBS and cellular 
extracts are prepared in buffer containing 20 mM Tris-Cl (pH 7.5), 300 mM NaCl, 3 mM 
EDTA, 3 mM EGTA, 100 mM Na3VO4, 1% NP-40, protease inhibitor cocktail. Cellular 
extracts containing 200 mg protein were immunoprecipitated with anti-cyclin B1 
antibody. Kinase assays were performed at 30 oC in 20 ml reaction buffer containing 20 
mM HEPES (pH7.5), 5 mM MgCl2, 2 mM EDTA, 2 mM EGTA, 1 mM dithiothreitol, 20 
mM ATP, 3 mg histone H1, and 10 mCi [g-32P] ATP. Reactions were terminated by adding 
2 ´ SDS-PAGE sample buffer, analyzed on a SDS-PAGE and visualized by 
autoradiography.   
 
Telomerase activity assay 
Telomerase activity was measured with the telomerase PCR- enzyme-linked 
immunosorbent assay (ELISA) kit (Roche) base on the telomeric repeat amplification 
protocol (TRAP) assay. Cells were suspended in lysis buffer (Roche), incubated on ice 
for 30 min, and then centrifuged at 14000 ´ g for 20 min. Supernatants were used for the 
detection of telomerase or flash frozen and stored at -80 oC. According to the 
manufacturer’s instructions, 200 ng of protein extract were assayed for telomerase 
activity after 30 cycles of amplification by PCR. The resulting PCR product (5 ul) was 
quantified by ELISA. Telomerase activity was expressed as absorbance values (OD) 
measured using a microtiter reader at 450 nm with a reference wavelength of 595 nm. All 
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assays were performed in duplicate and a dilution series of control telomerase extracts 
was always examined in parallel to give titration curve for normalizing experimental 
variations.  
RT-PCR analysis 
Analysis of the expression of hTERT and GAPDH were performed by reverse 
transcription-PCR amplification as previously described (Nakamura, 1997).   RNA was 
isolated with Trizol (invitrogen) according to the manufacturer. 1 µg of total RNA was 
reverse-transcribed using the RNA PCR kit version 2 (TaKaRa, Ohtsu, Japan) with oligo-
dT primers.  To amplify the cDNA, l aliquots of the reverse-transcribed cNNA (20ul) 
from 2 mg of RNA were subjected to PCR in 25 ul of 1x buffer (10mM Tris-Cl (pH8.3), 
1.5 mM MgCl2, 50 mM KCl), containing 1 mM each of the dNTP; 1.25 U of Taq NDA 
polymerase (TaKaRa); and 0.2 uM of specific primers. Primer sequence was chosen to 
amplify a 145-bp region presenting in all transcripts of hTERT mRNA 1784 (5’-
cggaagagtgtctggagcaa- 3’) and 1910 (5’- ggatgaagcggagtctgga- 3’) for 30 cycles (94oC 
for 30s, 60 oC for 30s, 72 oC for 90s).  As a positive control, GPDH mRNA was amplified 
in parallel using primers 5’-ctcagacaccatggggaaggtga- 3’ and 5’- atgatcttgaggctgttgtcata- 
3’ for 16 cycles (94oC for 30s, 55 oC for 30s, 72 oC for 45s). PCR products were 
electrophoresed in 15% polyacrylamide gel and stained with SYBR green. For semi-
quantification of hTERT mRNA expression, serially diluted cDNA reverse-transcribed 
from 2 mg RNA (corresponding to 50 ng to 1 mg RNA) was subjected to RT-PCR. 
Primers, probes for Real-time PCR 
Primers and prodes for the hTERT gene were chosen with the assistance of the 
Primer Express (Perkin-Elmer Applied Biosystems, Foster city, CA). To avoid 
 122 
amplification of contaminating genomic DNA, either upstream or downstream primer 
was placed in a different exon. Forward primer of hTERT1 (1909F) and probe1 was 
placed in exon 4, whereas reverse primer (2017R) was spanning exon 4 and 5 junction. 
Forward primer of hTERT2 (3081F) was spanning exon 13 and 14 junction, probe2 and 
reverse primer (3162R) in exon 14. The nucleotide sequences are as follows:  
hTERT1: 1909F: 5’-gtccagactccgcttcataa-3’; 2017R: 5’-gagacgctcggccctctt-3’; 
FAM/TAMRAprobe1: 5’-ttctggctcccacgacgtagtccatg-3’; PCR product size: 109bp. 
hTERT2: 3081F: 5’-cgtacaggtttcacgcatgtg-3’; 3162R: 5’-atgacgcgcaggaaaaatg-3’; 
TAM/TAMRAprobe2: 5’-agctcccatttcatcagcaagtttggaag-3’. PCR product size: 82bp. 
Real-time PCR 
RNA was prepared using the RNasy RNA isolation kit (Qiagen) and DNase 
digested on-column using RNase-free DNase set (Qiagen) and then reverse-transcribed. 
An RNA pool was generated by mixing aliquots of RNA from cells treated with vehicle 
or 1,25VD for various times. Concentrations of the pooled RNA ranging from 0 (buffer 
alone) to 50 ng/ml were used in the PCR analysis to generate the standard curve for each 
gene. The Ct value was generated by the ABI PRISM 7700 SDS software version 1.7 and 
then exported to an Excel spreadsheet where equations from the standard curve were 
generated. Using the Ct values, concentrations of the hTERT and GAPDH mRNAs were 
calculated from the equations. Each sample was analyzed at two different concentrations 
(50 ng/ml and 2 ng/ml) with only results in the most sensitive region of the standard curve 
presented. Samples at each concentration were analyzed in triplicates. hTERT levels were 
normalized to the corresponding input total RNA, base on quantitation of GAPDH.  
Telomere length analysis 
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 Telomere length was measured using a non-radioactive chemiluminescent assay 
developed by Roche Diagnostics. In brief, genomic DNA was isolated using a Roche 
DNA isolation kit. 5 mg DNA was digested overnight with 20 U of Hinf I and Rsa I, 
fractionalized on a 0.8% agarose gel. Gels were denatured for 30 min and then 
neutratlized for 30 min. DNA was transfered to a nylon membrane, hybridized with 
digoxigenin 3’- end tailing – labeled (Roche) (TTAGGG)4  oligonucleotides overnight at 
50 oC in PerfectHyb solution (Sigma). Membranes were washed twice in 2 x SSC, 0.1% 
SDS for 15 min at RT and twice in 0.1 x SSC, 0.1% SDS for 15 min at 50 oC. The probe 
was detected by the digoxigenin luminescence detection and processed by Southern 
blotting and chemiluminescent detection. The average telomere length can be determined 
by comparing the signals relative to a molecular weight standard.  
Immunohistochemical analysis 
To confirm the VDR and RXR expression in normal human tissue, paraffin-
embedded tissues were immunostained with anti-VDR antibody and anti-RXR antibody. 
The signal was detected with the avidin-biotin complex (ABC) immunoperoxidase kit 
(Vectastatin Elite ABC, Vector Laboratories, CA). The cell nucleus was counterstained 
with hematoxylin. Positive (skin tissue) and negative controls (pre-immune serum) were 
included in all immuno-reactions. 
Nude mouse tumor studies 
The studies were performed as described (Blutt, 2000) with little modification. 
Briefly, OVCAR3 cells were trypsinized and resuspended in 50% Matrigel Matrix 
(Becton Dickinson, San Jose, CA) at a concentration of 2x106 cells/100ul matrix. Female 
athymic nude mice, ~6 weeks of age, on a vitamin D-deficient diet supplemented with 
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1% calcium, received injections s.c. with 2x106 cells on the dorsal surface. After tumors 
grow to a volume of about 150mm3, the mice were randomly divided to three groups 
treated with placebo or EB1089 at 0.3 or 1.0mg/kg/day. EB1089 was delivered daily by 
gavage. The size of the tumor was determined by measuring the tumor diameters with a 
Vernier caliper every 5 days and using the formula tumor volume=dxDxD/2 (where d and 
D represent the shortest and the longest diameter, respectively).  
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